

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/157872/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Somogyi, Aleksandra, Kirkham, Emily D., Lloyd-Evans, Emyr , Winston, Jincy, Allen, Nicholas D. ORCID: <https://orcid.org/0000-0003-4009-186X>, Mackrill, John J., Anderson, Karen E., Hawkins, Phillip T., Gardiner, Sian E., Waller-Evans, Helen , Sims, Rebecca , Boland, Barry and O'Neill, Cora 2023. The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system. *Journal of Cell Science* 136 (6) , jcs259875. 10.1242/jcs.259875
filefile

Publishers page: <https://doi.org/10.1242/jcs.259875>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



RESEARCH ARTICLE

The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system

Aleksandra Somogyi^{1,2,3}, Emily D. Kirkham⁴, Emyr Lloyd-Evans⁴, Jincy Winston⁵, Nicholas D. Allen⁴, John J. Mackrill⁶, Karen E. Anderson⁷, Phillip T. Hawkins⁷, Sian E. Gardiner⁸, Helen Waller-Evans⁸, Rebecca Sims⁹, Barry Boland^{2,3,*} and Cora O'Neill^{1,3,*} ‡

ABSTRACT

Abnormalities in the endosomal-autophagic-lysosomal (EAL) system are an early event in Alzheimer's disease (AD) pathogenesis. However, the mechanisms underlying these abnormalities are unclear. The transient receptor potential channel mucolipin 1 (TRPML1, also known as MCOLN1), a vital endosomal-lysosomal Ca²⁺ channel whose loss of function leads to neurodegeneration, has not been investigated with respect to EAL pathogenesis in late-onset AD (LOAD). Here, we identify pathological hallmarks of TRPML1 dysregulation in LOAD neurons, including increased perinuclear clustering and vacuolation of endolysosomes. We reveal that induced pluripotent stem cell (iPSC)-derived human cortical neurons expressing APOE ε4, the strongest genetic risk factor for LOAD, have significantly diminished TRPML1-induced endolysosomal Ca²⁺ release. Furthermore, we found that blocking TRPML1 function in primary neurons by depleting the TRPML1 agonist PI(3,5)P₂ via PIKfyve inhibition, recreated multiple features of EAL neuropathology evident in LOAD. This included increased endolysosomal Ca²⁺ content, enlargement and perinuclear clustering of endolysosomes, autophagic vesicle accumulation and early endosomal enlargement. Strikingly, these AD-like neuronal EAL defects were rescued by TRPML1 reactivation using its synthetic agonist ML-SA1. These findings implicate defects in TRPML1 in LOAD EAL pathogenesis and present TRPML1 as a potential therapeutic target.

KEY WORDS: Alzheimer's disease, TRPML1, Ca²⁺, APOE, PIKfyve, Phosphoinositides

¹School of Biochemistry and Cell Biology, BioSciences Institute, University College Cork, T12 YT20 Cork, Ireland. ²Department of Pharmacology and Therapeutics, Western Gateway Building, University College Cork, T12 XF62 Cork, Ireland. ³Cork Neuroscience Centre (CNSC), University College Cork, T12 YT20 Cork, Ireland. ⁴School of Biosciences, Sir Martin Evans building, Cardiff University, CF10 3AX Cardiff, UK. ⁵UK Dementia Research Institute, Hadyn Ellis Building, Cardiff University, CF24 4HQ Cardiff, UK. ⁶Department of Physiology, School of Medicine, University College Cork, T12 YT20 Cork, Ireland. ⁷The Babraham Institute, Babraham Research Campus, CB22 3AT Cambridge, UK. ⁸Medicines Discovery Institute, Main Building, Cardiff University, CF10 3AT Cardiff, UK. ⁹Division of Psychological Medicine and Clinical Neuroscience, Cardiff University, C14 4XN Cardiff, UK.

*These authors contributed equally to this work

‡Authors for correspondence (c.oneill@ucc.ie; barry.boland@ucc.ie)

© A.S., 0000-0003-3079-2849; E.D.K., 0000-0002-6984-6579; E.L., 0000-0002-3626-1611; N.D.A., 0000-0003-4009-186X; J.J.M., 0000-0003-2473-129X; P.T.H., 0000-0002-6979-0464; H.W., 0000-0003-4133-6064; B.B., 0000-0003-2676-4343; C.O., 0000-0001-5386-7415

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Handling Editor: Giampietro Schiavo
Received 6 February 2022; Accepted 13 February 2023

INTRODUCTION

Increasing research evidence implicates defects in the endosomal-autophagic-lysosomal (EAL) system as a very early event in the genesis and progression of Alzheimer's disease (AD) pathology, including the buildup of amyloid-β (Aβ) and tau, and synaptic pathogenesis (Lie and Nixon, 2019; Nixon, 2017, 2020; Van Acker et al., 2019; van Weering and Scheper, 2019; Whyte et al., 2017). Furthermore, studies indicate that expression of the APOE ε4-encoding variant of apolipoprotein E (*APOE*) (Lin et al., 2018; Nuriel et al., 2017) is the greatest genetic risk factor for late onset AD (LOAD), which, along with many other LOAD risk genes and genes causing familial AD (Hung and Livesey, 2018; Kwart et al., 2019), converge to alter EAL function (Gao et al., 2018; Karch and Goate, 2015; Pimenova et al., 2018; Van Acker et al., 2019). However, it remains unclear which nodes of the EAL system are primarily affected in AD and, hence, could be targeted therapeutically to remediate AD pathogenesis.

The transient receptor potential channel mucolipin 1 (TRPML1; also known as MCOLN1) is a non-selective cation channel that can transport Ca²⁺, Fe²⁺ and Zn²⁺ (Dong et al., 2008; Kiselyov et al., 2011). The primary function of TRPML1 is to induce Ca²⁺ release from endolysosomal compartments, a vital process for endolysosomal function (Di Paola et al., 2018; Venkatachalam et al., 2015; Waller-Evans and Lloyd-Evans, 2015). TRPML1 is highly expressed in the brain (Samie et al., 2009) and, although not investigated with respect to EAL pathogenesis in LOAD, regulates many EAL functions known to be impaired in AD neurons. The functions regulated by TRPML1 include: maturation of late endosomes to lysosomes; endolysosomal trafficking; nutrient sensing and adaptation; positioning, exocytosis, fission, clearance and reformation of lysosomes; autophagy, phagocytosis and clearance of aggregated proteins and pathogens (reviewed in Di Paola and Medina, 2019; Di Paola et al., 2018; Huang et al., 2020; Kendall and Holian, 2021; Li et al., 2019). Loss-of-function mutations in the human TRPML1 gene *MCOLN1* cause mucopolidosis type IV (MLIV) (Bargal et al., 2001; Bassi et al., 2000; Slaugenhaupt, 2002; Sun et al., 2000), a rare recessive lysosomal storage disorder (LSD). MLIV is characterized by neurodegeneration, psychomotor impairment, ophthalmologic and gut defects (Boudewyn and Walkley, 2019). MLIV patient cells show multiple EAL abnormalities including defective endolysosomal trafficking, vacuolation, altered positioning of the endolysosomal compartment, compromised maturation of lysosomes, dysregulated pH and autophagic defects (for a review, see Boudewyn and Walkley, 2019; Cheng et al., 2010; Puertollano and Kiselyov, 2009).

The link between endolysosomal TRPML1 dysfunction and neurodegenerative disease is further supported by findings that TRPML1-mediated Ca²⁺ release is impaired in other LSDs,

including Niemann–Pick C (NPC) disease (Lloyd-Evans and Platt, 2011; Shen et al., 2012). NPC disease shares the pathological features of tau and A β accumulation with AD (Lloyd-Evans et al., 2008). Furthermore, although not yet examined in LOAD, alterations in TRPML1 function are associated with deletion of the presenilin-1 (PS-1; also known as *PSEN1*) gene, which causes familial AD (FAD) (Lee et al., 2015, 2010; Lie et al., 2022). TRPML1 function is implicated in autophagic clearance of A β and tau in AD by being the primary activator of transcription factor EB (TFEB), the major regulator of lysosomal biogenesis and autophagy (Medina et al., 2015; Napolitano and Ballabio, 2016; Zhang et al., 2016). TFEB activation promotes clearance of A β and tau pathology in preclinical models of AD (Akwa et al., 2023; Martini-Stoica et al., 2018; Polito et al., 2014; Song et al., 2020; Xiao et al., 2015; Xu et al., 2020), where TRPML1 activation has been shown to be essential for TFEB-mediated clearance of tau-induced pathology (Xu et al., 2020). Recent studies show that TRPML1-dependent lysosomal Ca²⁺ release regulates dendritic lysosomal trafficking and hippocampal neuronal function (Sun et al., 2022).

TRPML1 is one of the few ion channels gated by phosphoinositide (PI) lipids, with PI(3,5)P₂ being the primary and only identified endogenous agonist of TRPML1 (Dong et al., 2010; Zhang et al., 2012), and PI(4,5)P₂ the TRPML1 antagonist (De Leo et al., 2016; Feng et al., 2014; Zhang et al., 2012). PI metabolism is central to effective vesicular trafficking in the EAL system (Balla, 2013; Di Paolo and De Camilli, 2006) and attention has been drawn to defects in PI metabolism in the AD brain (Morel et al., 2013; Stokes and Hawthorne, 1987; Zhu et al., 2015) and as a target of LOAD risk genes (reviewed in Raghu et al., 2019). Another interesting feature of this system is that PI(3,5)P₂, the TRPML1 agonist, is synthesized exclusively by the PIKfyve kinase complex (McCartney et al., 2014). In concordance, inhibition of the PIKfyve complex recreates endolysosomal defects similar to those in MLIV, typified by vacuolation of endolysosomal compartments (Bissig et al., 2017; Chen et al., 2017; Choy et al., 2018; Dong et al., 2010; Ikonov et al., 2002, 2001; Jefferies et al., 2008; Kim et al., 2014; Martin et al., 2013; McCartney et al., 2014). Furthermore, as with TRPML1, mutations in the human PIKfyve complex, namely the FIG4 and Vac14 components, lead to neurodegeneration – in this case, including amyotrophic lateral sclerosis (ALS), Charcot–Marie–Tooth disease, and Yunis–Varon syndrome (Campeau et al., 2013; Chow et al., 2009; Chow et al., 2007; Lines et al., 2017; Nicholson et al., 2011; Zhang et al., 2008).

Interestingly, recent studies have shown that loss of PIKfyve activity drives spongiform neurodegeneration and neuronal vacuolation in prion disease, which can be rescued by PI(3,5)P₂ supplementation (Lakkaraju et al., 2021). Conversely, other publications show that PIKfyve inhibition reduces the transport of tau and α -synuclein from early to late endolysosomes *in vitro*, preventing their fibrillization, which is thereby considered as neuroprotective (See et al., 2021 preprint; Soares et al., 2021). Together, this draws attention to investigating the potential mechanistic link between PIKfyve activity and TRPML1 function in the context of EAL neuropathogenesis in LOAD and other neurodegenerative diseases. It has been suggested that activation of TRPML1 might represent a protective strategy against EAL defects in LOAD (Hui et al., 2019). Importantly, synthetic small-molecule compounds, including mucolipin synthetic agonist 1 (ML-SA1) have been developed as PI(3,5)P₂-independent specific TRPML1 agonists (Fine et al., 2020; Grimm et al., 2010; Shen et al., 2012). ML-SA1 has been shown to protect against Alzheimer's-like A β pathology in other neurological conditions, particularly

HIV-1-associated neurocognitive disorders (Bae et al., 2014; Hui et al., 2019, 2021). Furthermore, ML-SA1 protects against endolysosomal pathology caused by FIG4 deficiency (Zou et al., 2015). However, whether these TRPML1 agonists can protect against potential EAL pathogenesis due to direct PIKfyve inhibition in neurons is unknown.

In this study, we hypothesized that dysregulation of TRPML1-mediated endolysosomal function is an underlying component of EAL neuropathogenesis in LOAD. Therefore, we aimed to determine whether indicators of TRPML1 function were altered in LOAD patient brains and in induced pluripotent stem cell (iPSC)-derived neurons expressing APOE ϵ 4 compared to cells with other APOE isoforms. We further investigated whether it was possible to model key AD-related EAL phenotypes in primary neurons by inactivating TRPML1 via inhibition of PI(3,5)P₂ production, using the PIKfyve inhibitor YM201636. Finally, we investigated whether targeting TRPML1 with ML-SA1 in primary neurons could provide a novel approach to remediate AD-related EAL defects induced by PIKfyve inhibition.

RESULTS

Endolysosomal neuropathology in the AD brain and altered phosphoinositide dynamics indicate abnormalities in TRPML1 function

TRPML1 function and PI dynamics closely relate to endolysosomal integrity (Cao et al., 2017; Zhang et al., 2012). We thus first interrogated endolysosomal integrity in post-mortem AD brain tissue using an antibody against the endogenous endolysosomal marker LAMP1, performing immunofluorescence microscopy of post-mortem hippocampal sections from AD patients ($n=10$) and matched controls ($n=10$) (Table 1). Our results demonstrated an increase in LAMP1-positive endolysosomes, which was particularly evident in the perinuclear region of hippocampal cells in the CA1 and CA3 regions, in AD cases compared to in the matched controls (Fig. 1A–C). A 3D reconstruction of LAMP1 immunoreactivity and positioning in a morphologically identifiable CA1 pyramidal neuron in AD compared to control pyramidal neurons is shown in Fig. 1B. Quantification, using CellProfiler, revealed that LAMP1 intensity was significantly increased in the perinuclear area of cells in the CA1 region in AD compared to in control cases (Fig. 1D,E).

We performed double immunofluorescence with LAMP1 and the astrocytic marker GFAP to investigate the cellular localisation of LAMP1 pathogenesis in the AD brain. Here, our results showed that increased levels of LAMP1-positive endolysosomes were observed in the perinuclear regions of GFAP-negative pyramidal neurons in the AD hippocampus (Fig. S1A). GFAP-labelled astrocytes with increased levels of LAMP1 immunoreactivity in perinuclear regions were also identified in the AD hippocampus (Fig. S1A).

Deletion of TRPML1 in MLIV and inhibition of the synthesis of the TRPML1 agonist PI(3,5)P₂ induce endolysosomal defects including perinuclear clustering, as described above, as well as enlargement of endolysosomal vesicles (Dong et al., 2010; McCartney et al., 2014; Zhang et al., 2012). Notably, vacuolisation of LAMP1-positive vesicles was observed in cells with the morphology of neurons in the CA3 region in AD cases (Fig. 1C). Quantification using ImageJ revealed a significant increase in the number of enlarged LAMP1-positive vesicles in the CA3 region in AD compared to in control cases (Fig. 1F). Vacuoles were defined as large membrane-bound vesicular structures immunoreactive to LAMP1. These vacuoles were larger than vesicles (~ 4 – 10 μm diameter). In granulovacuolar degeneration

Table 1. Clinical and post-mortem details of cases used in this study

Cases	Gender	Age (years)	Braak stage	Plaques	PMD (h)	Tissue pH	Brain weight (g)
Immunofluorescence analysis							
Control							
C1	M	93	0	A	07:40	6.20	1155
C2	F	72	I	A	06:50	7.22	1165
C3	F	88	II	O	05:35	6.89	1132
C4	F	76	II		04:45	6.40	1140
C5	M	95	II	B	07:15	6.56	1387
C6	F	93	II	O	07:35	6.27	1025
C7	F	89	III		06:35	6.73	1139
C8	M	88	III	B	07:00	6.76	1230
C9	M	92	III	B	07:45	6.55	1210
C10	F	95	III	B	07:10	6.32	955
C11	F	81	II		07:40	6.60	1180
Alzheimer's disease							
A1	F	92	IV	B	07:25	6.10	1081
A2	F	88	IV	C	06:43	6.24	960
A3	M	73	V	C	04:45	6.48	1205
A4	M	78	V	C	05:55	6.40	1275
A5	M	82	V	C	04:25	5.95	1225
A6	F	84	V	C	04:50	6.26	948
A7	M	81	VI	C	07:50	6.15	1120
A8	F	66	VI	C	04:12	6.47	915
A9	F	90	VI	C	05:40	6.60	1070
A10	F	91	VI	C	04:20	6.32	900
A11	F	89	VI	C	08:24	6.60	1065
Western blot analysis							
Control							
C1	F	61	0	O	06:50	6.50	1422
C2	F	77	I	A	08:20	6.48	1212
C3	F	82	I	A	05:30	6.60	1260
C4	F	84	I	O	04:45	6.26	1104
C5	M	79	I	A	05:20	6.72	1262
C6	M	85	I	O	04:15	6.68	1121
Alzheimer's disease							
A1	F	84	V	C	04:50	6.26	948
A2	M	65	V	C	07:20	6.47	1173
A3	M	78	V	C	07:45	6.40	1208
A4	M	85	V	C	04:45	6.38	1215
A5	F	61	VI	C	06:25	6.62	1072
A6	F	82	VI	C	06:00	6.48	1010
Phosphoinositide analysis							
Control							
C1	M	93	0	A	07:40	6.20	1155
C2	F	72	I	A	06:50	7.22	1165
C3	F	76	II		04:45	6.40	1140
C4	M	95	II	B	07:15	6.56	1387
C5	F	93	II	O	07:35	6.27	1025
C6	F	89	III		06:35	6.73	1139
C7	M	88	III	B	07:00	6.76	1230
C8	M	92	III	B	07:45	6.55	1210
C9	F	95	III	B	07:10	6.32	955

Continued

Table 1. Continued

Cases	Gender	Age (years)	Braak stage	Plaques	PMD (h)	Tissue pH	Brain weight (g)
C10	M	89	II	O	06:50	6.23	1185
C11	F	78	I	A	07:10	6.32	1120
C12	F	60	0	O	08:10	6.58	1310
Alzheimer's disease							
A1	F	92	IV	B	07:25	6.10	1081
A2	F	88	IV	C	06:43	6.24	960
A3	M	73	V	C	04:45	6.48	1205
A4	M	78	V	C	05:55	6.40	1275
A5	M	82	V	C	04:25	5.95	1225
A6	F	84	V	C	04:50	6.26	948
A7	M	81	VI	C	07:50	6.15	1120
A8	F	66	VI	C	04:12	6.47	915
A9	F	90	VI	C	05:40	6.60	1070
A10	F	91	VI	C	04:20	6.32	900
A11	F	94	V	C	04:30	7.33	1021
A12	M	76	VI	C	05:10	6.32	1116

PMD, post-mortem delay; h, hours; g, grams; M, male; F, female.

(GVD), described to occur in the AD brain (Funk et al., 2011; Kohler, 2016; Thal et al., 2011), vacuoles are described to be 3–5 μm and to have a dense central core or central granule of 0.5–1.5 μm , which was not evident in the vacuoles we show. We attempted to determine whether these vacuoles were similar to those observed in GVD, using casein kinase-1 δ (CK-1 δ), a marker for the granulovacuolar granule (Funk et al., 2011) and double immunofluorescence with LAMP1. However, immunofluorescence analysis with CK-1 δ antibody did not reveal clear granulovacuolar granule staining (data not shown).

In the AD cases, increased LAMP1 immunoreactivity was greater in areas where many cells accumulated PHF-1 immunoreactive tau (Fig. 1G, right) and was strongly enriched around senile plaques (Fig. 1H). The observation that LAMP1 immunoreactivity is enriched in plaques has been described in the AD brain (Barrachina et al., 2006) and in preclinical mouse AD models (Condello et al., 2011; Gowrishankar et al., 2015; Kandalepas et al., 2013). Control and AD brain material was staged for disease severity (Braak staging 0–VI, see Materials and Methods). Alterations in the levels of LAMP1 and endolysosomal enlargement were specific to AD cases irrespective of their Braak stage. However, western immunoblot analysis (Fig. 1I) and quantification (Fig. 1J) of temporal cortex membrane fractions prepared from AD and control brain showed only a non-significant trend towards an increase in LAMP1 levels in many AD samples compared with control levels, which is in line with previous literature (Bordi et al., 2016), and points rather to a shift in localization resulting in regional accumulation of lysosomes in the perinuclear region.

As TRPML1 is a PI-gated ion channel (Dong et al., 2010; Feng et al., 2014a; Fine et al., 2018; Hille et al., 2015), which relies heavily on effective PI dynamics, we thought it important to determine whether levels of all measurable PIs were altered in the AD brain. We quantified individual and total PI levels in brain tissue of the AD and age-matched control groups using advanced mass spectrometry approaches (Kielkowska et al., 2014). Results demonstrated that levels of total PIP₃ [PI(3,4,5)P₃] and total PIP₂ [regioisomers PI(4,5)P₂, PI(3,4)P₂ and PI(3,5)P₂] were significantly increased ($P < 0.05$) in the mid temporal cortex of AD patients

(Braak IV–VI, $n=12$) compared to age-matched controls (Braak 0–III, $n=12$) (Table 1; Fig. 2). No significant differences were detected in PI or total PIP [PI3P, PI4P and PI5P] levels when comparing AD and control groups (Fig. 2). There was no correlation between PI levels and post-mortem delay in these samples. Regioisomer classification of the primary (> 75%) lipid species (stearoyl/arachidonoyl, 'C38:4') showed that increased PIP₂ levels represented PI(4,5)P₂, as no PI(3,4)P₂ levels were detected (data not shown). Unfortunately, PI(3,5)P₂, the major agonist of TRPML1, cannot be distinguished yet using mass spectrometry methodology as the abundance of this lipid species is extremely low (Michell et al., 2006). Significantly, PIP₃, whose levels we show to be increased in the AD group, is the major activator of Akt protein kinases, which are known to be hyper-activated in AD neurons (Griffin et al., 2005; Moloney et al., 2010) and which are a primary regulator of EAL dynamics via the mTOR signalling axis (Boland et al., 2018). Taken together, the PI changes observed in AD brains reflect significant defects in overall PI network integrity that have the potential to impact TRPML1 and endolysosomal function in AD.

We performed western immunoblot and immunofluorescence analysis with TRPML1 antibodies in control and AD brain. TRPML1 antibodies have been criticised due to possible non-specificity and we found variability in antigenicity and immunoblot profiles between TRPML1 antibody batches (Fig. S1B,C). Thus, we were unable to make a definitive conclusion on whether the levels or subcellular localisation of TRPML1 were altered in the AD brain compared to matched controls. Nonetheless, we have included representative immunoblots and immunofluorescence analysis of TRPML1 in control and AD cases in Fig. S1B–D.

Lysosomal Ca²⁺ levels are increased and TRPML1 activity is decreased in homozygous APOE $\epsilon 4$ neurons

Enlargement of the endolysosomal system has also been described in APOE $\epsilon 4$ modified cell systems *in vivo* (Nuriel et al., 2017; Xian et al., 2018), reflecting our findings in neurons in the LOAD brain. A major functional consequence of defective TRPML1 function is impaired Ca²⁺ efflux from late endolysosomes. TRPML1 activity is not measurable in post-mortem brain tissue. We thus applied a more




Fig. 1. See next page for legend.

dynamic physiological measurement of endolysosomal Ca^{2+} in an *APOE*-modified AD neuronal system where we differentiated human iPSC-derived neurons from cells expressing isogenic *APOE* $\epsilon 3$, *APOE* $\epsilon 4$ and *APOE* $\epsilon 2$, and *APOE*^{-/-} cells (Schmid et al., 2019). Measurement of endolysosomal Ca^{2+} was obtained by

imaging Fura2-AM-labelled iPSC neurons that were first treated with the Ca^{2+} ionophore ionomycin (2 μM), which induces Ca^{2+} release from the endoplasmic reticulum (ER), followed by the lysosomal membrane disrupting agent, glycyl-L-phenylalanine 2-naphthylamide (GPN, 500 μM) to release endolysosomal Ca^{2+}

Fig. 1. Increased levels and altered subcellular distribution of LAMP1-positive endolysosomes in the AD brain. (A,C) Representative images showing the accumulation and swelling of LAMP1-positive vesicles in cells of the CA1 (A) and CA3 (C) regions of hippocampal sections of AD ($n=10$) and control cases ($n=10$). Scale bars: 20 μm . Detailed sections of single neurons are shown in bottom panel of C. Scale bars: 5 μm . (B) Surface-rendered 3D reconstruction of LAMP1-positive vesicles in a morphologically identified CA1 pyramidal neuron of an AD patient and control. Scale bars: 10 μm . (D,E) Quantification of LAMP1 intensity in the CA1 region (D) and specifically in the perinuclear area (E) from $n=6$ AD cases and $n=8$ control cases with 2–5 representative images analysed for each case, together analysing $n=26$ control images and $n=26$ AD images. (F) Quantification of the number of enlarged LAMP1 immunoreactive vesicles per neuron in the CA3 region. (G) Representative images showing increased LAMP1 immunoreactivity in cells of the CA1 region accumulating PHF-1 immunoreactive tau in AD patients ($n=10$, right) and control ($n=10$, left), and areas of AD CA1 with little PHF1 immunoreactive tau (middle). (H) Representative image of LAMP1 localisation to senile plaques decorated with PHF-1 immunoreactive tau ($n=10$ AD cases). (I) Western immunoblot analysis of temporal cortex membrane fractions ($n=6$) showing a trend towards increased LAMP1 levels in AD patients compared with controls (n.s.). LiCor total protein stain was used to ensure equal loading. (J) Quantification of LAMP1 immunoblot data. Data are expressed as mean \pm s.e.m. * $P<0.05$; ** $P<0.01$ (unpaired two-tailed Student's t -test).

into the cytosol (Bergling et al., 1998; Sage et al., 2011). Hence, the resulting elevation in fluorescence of the Ca^{2+} probe allows for an estimation of the lysosomal Ca^{2+} content. Using this experimental paradigm, we found that neurons expressing APOE $\epsilon 4$, the greatest genetic risk factor for LOAD, had significantly higher levels of lysosomal Ca^{2+} compared with APOE $\epsilon 3$ ($P=0.0102$), APOE $\epsilon 2$ ($P<0.0001$) and APOE $^{-/-}$ ($P<0.0001$) neurons (Fig. 3A).

We performed further experiments to measure lysosomal Ca^{2+} *in situ* with Oregon Green-conjugated BAPTA 5N (OGB) and Texas Red-conjugated dextran as a loading control (Fig. 3B). Although not significant compared with APOE $\epsilon 3$ and APOE $\epsilon 2$, the trend seen in these data further confirms that lysosomal Ca^{2+} is indeed elevated in APOE $\epsilon 4$ -expressing iPSC neurons ($P=0.0116$ versus APOE $^{-/-}$). As Ca^{2+} accumulation itself and the K_D of OGB are affected by endolysosomal vacuolar pH (Gerasimenko et al., 1998), we measured endolysosomal pH, using a pH-sensitive FITC-dextran alongside Texas Red-dextran as loading control. Our results show that endolysosomal pH is not changed in any of the APOE isoform-expressing cortical neurons (Fig. 3C,D). This removes any concerns about possible alterations in vacuolar pH in these neurons. It also gives confidence that GPN in these neurons is being hydrolysed correctly and that the Ca^{2+} buffering capacity of OGB was unchanged.

To assess endogenous TRPML1 activity in finer detail, these neurons were treated with low concentrations (200 nM) of bafilomycin A1 (BafA1), which causes a mild increase in lysosomal pH (Yoshimori et al., 1991), indicated to increase TRPML1-mediated Ca^{2+} release (Lee et al., 2015; Li et al., 2017). Following, BafA1 addition, the number of spontaneous Ca^{2+} sparks was counted during a 5-min period. Results demonstrate that APOE $\epsilon 3$, APOE $\epsilon 2$ and APOE $^{-/-}$ neurons had an average of 1.71 ± 0.03 , 1.63 ± 0.03 and 1.49 ± 0.04 spontaneous Ca^{2+} sparks/min, respectively (mean \pm s.e.m.). In contrast, APOE $\epsilon 4$ neurons had a significantly lower number of spontaneous Ca^{2+} sparks/min (1.16 ± 0.03 , $P<0.0001$) (Fig. 4A,B). To determine whether these Ca^{2+} sparks were TRPML1 mediated, neurons were pre-treated with the TRPML1 inhibitor GW405833, a close analogue of ML-S11 (Rautenberg et al., 2022). Upon TRPML1 inhibition, the number of spontaneous Ca^{2+} sparks were significantly reduced ($P<0.001$, Fig. 4A,B) to 1.30 ± 0.04 and 1.33 ± 0.05 sparks/min in APOE $\epsilon 3$ and




Fig. 2. Levels of phosphoinositides with the potential to regulate TRPML1 are altered in the temporal cortex of AD patients. HPLC-MS analysis of PI per PI-internal standard (PI/PI-SD), as described in the Materials and Methods. Levels of total PIP, PIP₂ and PI(3,4,5)P₃ in mid temporal cortex tissue of AD ($n=12$) and control ($n=12$) groups. Levels of total PIP₃ [PI(3,4,5)P₃] and total PIP₂ [PI(4,5)P₂, PI(3,4)P₂ and PI(3,5)P₂], were significantly increased (* $P<0.05$, unpaired two-tailed Student's t -test) in AD cases compared to controls. Regio-isomer classification showed that increased total PIP₂ levels in AD cases represented PI(4,5)P₂ (data not shown). Data are expressed as mean \pm s.e.m.

APOE $\epsilon 2$ neurons, respectively (Fig. 4A,B) and to 1.36 ± 0.04 sparks in APOE $^{-/-}$ neurons ($P=0.016$). In contrast, APOE $\epsilon 4$ neurons showed no change in the number of spontaneous sparks/min upon TRPML1 inhibition (Fig. 4A,B).

Treatment with the synthetic TRPML1 agonist ML-SA1, which locks the endolysosomal TRPML1 channel non-physiologically in an open conformation (Feng et al., 2014b), showed that ML-SA1 could induce TRPML1-mediated Ca^{2+} release regardless of the APOE isoform expressed (Fig. 4C). The ML-SA1-induced Ca^{2+} release was not significantly different when comparing APOE isoforms, although there was a trend towards increased Ca^{2+} release in the APOE $\epsilon 4$ cortical neurons (Fig. 4C). This increase is most likely due to an ER compensatory effect, as ER Ca^{2+} release was not blocked in these experiments, and the fact that ML-SA1 locks the channel in an open conformation.

The cation selectivity for TRPML1 channels has been described to include Ca^{2+} , Fe^{2+} and Zn^{2+} (Dong et al., 2008; Kiselyov et al., 2011). We performed experiments using the FluoZin3(AM) probe to detect Zn^{2+} accumulation in endolysosomes. Our results show that there were no significant differences in Zn^{2+} levels between the cortical neurons expressing the different APOE isoforms (Fig. S2A–E). This is not surprising, as Zn^{2+} accumulation in cells with a TRPML1 defect is only observed when the cells are grown in 100 μM extracellular Zn^{2+} (Minckley et al., 2019). We did not investigate this, as this concentration of ZnCl_2 is toxic to cells. The Fura-2 fluorophore can detect Zn^{2+} in theoretical experimental conditions when Zn^{2+} concentrations are high (Martin et al., 2006). These Zn^{2+}




Fig. 3. Increased lysosomal Ca²⁺ levels in a neuronal LOAD iPSC model. (A) APOE ε3, APOE ε4, APOE ε2 or APOE^{-/-} iPSC neurons were loaded with Fura2-AM and treated with ionomycin followed by GPN to release lysosomal Ca²⁺. Representative traces (i) and quantification (ii) of GPN-induced Ca²⁺ release following ionomycin pre-treatment. (B) Quantification of *in situ* Ca²⁺ levels as fluorescence ratio between the Ca²⁺-sensitive OGB (0.5 mg/ml) and Ca²⁺-insensitive Texas Red-Dextran (0.1 mg/ml) as loading control in *n*=5 biological replicates, *n*=1 technical replicate per APOE isoform. (C,D) Quantification (C) and representative images (D) of APOE ε3, APOE ε4, APOE ε2 or APOE^{-/-} iPSC neurons loaded with pH-sensitive FITC-dextran (0.5 mg/ml) and pH-insensitive Texas Red-dextran (0.25 mg/ml), as loading control, showed no difference in lysosomal pH. Scale bars: 10 μm.

concentrations are not attained in the cellular context (Bozym et al., 2010, 2006), where Fura-2 has been shown to be unable to respond to the small physiological changes in cellular Zn²⁺ concentrations (Krezel and Maret, 2006). TPEN can be used as a cell permeant Zn²⁺ chelator. However, we did not employ TPEN in these studies, as it also chelates Ca²⁺ (Morgan et al., 2012).

Notably, increased cathepsin D levels have been described previously in AD neurons (Cataldo et al., 1995, 1991). We used BODIPY-pepstatin as an indicator of cathepsin D activity (Chen et al., 2000). Our results show BODIPY-pepstatin fluorescence was altered in APOE ε4 neurons, with significantly increased BODIPY-pepstatin total spot fluorescence ($P=0.0021$ versus APOE ε2, $P=0.0153$ versus APOE^{-/-}) and spot area ($P=0.0134$ versus APOE ε2) in APOE ε4 neurons compared to other APOE isoforms (Fig. S2F–H). There was also a trend towards fewer BODIPY-pepstatin fluorescent spots per cell in the APOE ε4 neurons, but this was not significant (Fig. S2I). These data indicate that there are increased levels of active cathepsin D in APOE ε4 neurons, further indicating, albeit indirectly, that lysosomes are not de-acidified in APOE ε4 neurons.

Together, our results indicate that APOE ε4 neurons, which model genetic risk for LOAD, have significantly higher levels of endolysosomal Ca²⁺ and are unable to release Ca²⁺ via TRPML1 in response to induced mild deacidification of endolysosomal compartments. These defects in the ability of TRPML1 to release Ca²⁺ in APOE ε4 neurons occur in the absence of any alteration in endolysosomal pH or endolysosomal Zn²⁺ levels.

Inhibition of PIKfyve causes AD-like increases in endolysosomal Ca²⁺ content, which are rescued by the TRPML1 agonist ML-SA1

PI(3,5)P₂ is currently the only known endogenous agonist of TRPML1 (Dong et al., 2010; Zhang et al., 2012). Thus, inhibition of

PIKfyve, the unique PI(3,5)P₂-synthesising enzyme complex, by the pharmacological inhibitors YM201636 (Jefferies et al., 2008) and apilimod (Cai et al., 2013) deprives TRPML1 of its agonist and replicates many endolysosomal defects caused by loss of TRPML1 function in non-neuronal systems (Cai et al., 2013; Dong et al., 2010; Jefferies et al., 2008; McCartney et al., 2014). Having described TRPML1-related endolysosomal defects in AD neurons and diminished TRPML1 activity in APOE ε4-expressing iPSC-derived neurons, we were next interested to determine whether these TRPML1 defects could be replicated by PIKfyve inhibition in primary neurons. Here, it is possible to link the effects of PIKfyve inhibition specifically to TRPML1 function within neurons, by investigating whether the small synthetic TRPML1 agonist ML-SA1 protects against any EAL phenotypes induced by PIKfyve inhibition. This was of major interest, as it has not been investigated previously, and allows evaluation of the therapeutic potential of ML-SA1 and thus TRPML1 activation, to protect against AD-like endolysosomal phenotypes in a neuronal model system (Fig. 5A).

Firstly, we treated primary rat cortical neurons with YM201636. Endolysosomal Ca²⁺ content was measured in a similar manner to that in human APOE-modified neurons – modifications of the protocol are described in the Materials and Methods and included differing Fura-2 concentrations due to the lysosomal Ca²⁺ release levels in rat primary cortical neurons and lesser sensitivity of the camera used. Our results show that endolysosomal Ca²⁺ levels were significantly increased ($P<0.0001$) in the presence of 4 μM YM201636 for 6 h (1.62 ± 0.10 fold, data not shown; mean \pm s.e.m.) and 24 h (1.63 ± 0.07 fold), respectively (Fig. 5B). Notably, although scale and effect size are different, this pharmacological inhibition of PIKfyve in rat primary neurons replicates the increased endolysosomal Ca²⁺ content we detected in APOE ε4 neurons. Furthermore, when these neurons were




Fig. 4. Decreased TRPML1-mediated lysosomal Ca²⁺ release in a neuronal LOAD iPSC model. (A,B) APOE ε3, APOE ε4, APOE ε2 or APOE^{-/-} iPSC neurons were loaded with Fura2-AM and treated with the IP₃ receptor antagonist xestospongin C to block Ca²⁺ efflux from the ER, followed by BafA1 to mimic age-related mild deacidification. TRPML1 activity was assessed by counting spontaneous sparks of Ca²⁺ release during a 5-min period in the presence [APOE ε3 (*n*=11, 235 traces), APOE ε4 (*n*=12, 243 traces), APOE ε2 (*n*=10, 226 traces), APOE^{-/-} (*n*=11, 257 traces)] or absence [APOE ε3 (*n*=6, 90 traces), APOE ε4 (*n*=6, 101 traces), APOE ε2 (*n*=6, 130 traces), APOE^{-/-} (*n*=7, 163 traces)] of the TRPML1 inhibitor GW405833 (10 μM). The response of representative cells is depicted and expressed as the 340/380 nm ratio of Fura2-AM fluorescence. Representative traces (A) and quantification (B) of spark number/minute induced by BafA1. Significance levels were calculated between all samples without GW405833 to detect APOE isoform-specific alterations in TRPML1 response (**P*<0.05; ***P*<0.01; ****P*<0.001, one-way ANOVA followed by Bonferroni post-hoc test) and for each APOE isoform between GW405833-treated and untreated sample to assess TRPML1 contribution (#*P*<0.05; ###*P*<0.001, unpaired two-tailed Student's *t*-test). (C) Quantification of full physiological cellular Ca²⁺ release after addition of 10 μM ML-SA1 including, but not limited to lysosomal Ca²⁺ stores in *n*=3 biological replicates, *n*=1 technical replicate per APOE isoform. Data are expressed as mean±s.e.m.

co-treated with ML-SA1 (50 μM), the accumulated Ca²⁺ was released from the lysosomes and the size of lysosomal Ca²⁺ stores were restored to the levels of vehicle-treated cells (*P*=0.0003) (Fig. 5B). ML-SA1 treatment alone did not deplete lysosomal Ca²⁺ stores within the time frames used in this study (Fig. 5C). Together, these results indicate that therapeutic activation of TRPML1 has the potential to protect against increased lysosomal Ca²⁺ levels in primary neurons such as those evident in APOE ε4 LOAD model systems.

Inhibition of PIKfyve replicates AD-like perinuclear accumulation and vacuolation of endolysosomal compartments, which are rescued by the TRPML1 agonist ML-SA1

Next, we determined whether the perinuclear accumulation and vacuolation of endolysosomes we describe in AD neurons could be replicated by PIKfyve inhibition, and whether this could be rescued by activation of TRPML1 with ML-SA1. Here, we employed the endolysosomal marker Rab7 (Ginsberg et al., 2010), which performed better as an endolysosomal marker in primary neurons when compared to LAMP1. Furthermore, Rab7 is critical for effective late endolysosomal function, including lysosomal biogenesis and positioning in the perinuclear region (for review see Guerra and Bucci, 2016). Our results revealed that YM201636

treatment induced a striking increase in the intensity of perinuclear Rab7 (herein referring to Rab7a) immunoreactivity (Fig. 6A), resembling the perinuclear accumulation of LAMP1 in CA1 neurons of AD patients (Fig. 1A,B). These Rab7-immunopositive vesicles included enlarged vacuoles within the soma, which were decorated with Rab7 immunoreactivity (Fig. 6A, zoom), as is typical for PIKfyve inhibition in many cell types (Bissig et al., 2017; Chen et al., 2017; Choy et al., 2018; Dong et al., 2010; Ikononov et al., 2002, 2001; Jefferies et al., 2008; Kim et al., 2014; Martin et al., 2013; McCartney et al., 2014) and is similar to vesicles seen in the CA3 region of AD patients (Fig. 1C). Specifically, YM201636 treatment exhibited a dose- and time-dependent effect to markedly and significantly increase the number and size of Rab7-immunopositive vesicles in primary neurons (Fig. 6A).

Notably, the colocalisation of Rab7 within and surrounding the enlarged vacuoles was the most selective when comparing it with that of several other endosomal-lysosomal markers including Rab5 (herein referring to Rab5a–Rab5c), EEA1 and lysobisphosphatidic acid (LBPA) (Fig. S3). Importantly, we further show that co-treatment of primary neurons with 4 μM YM201636 and 50 μM ML-SA1 led to both a significant reduction in the intensity of Rab7 immunopositive vesicles in the perinuclear region and a highly significant reduction in the number of vacuoles that were immunolabelled with Rab7 at 24 h, both of which were restored




Fig. 5. ML-SA1 rescues YM201636-mediated Ca²⁺ accumulation in rat primary cortical neurons. (A) Scheme of TRPML1 inactivation by PIKfyve inhibition and reactivation by ML-SA1. (B) Lysosomal Ca²⁺ was measured in neurons loaded with Fura2-AM, using 500 μ M GPN to release lysosomal Ca²⁺ following a 2 μ M ionomycin pre-treatment to clamp all other intracellular Ca²⁺ stores, in rat primary cortical neurons pre-treated with 4 μ M YM201636 (red, $n=6$, 72 traces) for 24 h when compared to vehicle (veh, black, $n=7$, 118 traces) only. Co-treatment with 50 μ M ML-SA1 (grey, $n=6$, 77 traces) restored the lysosomal Ca²⁺ pool. Representative trace (left) and quantification (right). (C) Rat primary cortical neurons were pre-treated with either 50 μ M ML-SA1 (grey, $n=3$, 388 traces) or vehicle (black, $n=3$, 381 traces) for 24 h. Lysosomal Ca²⁺ content was measured as in B, but no change was detected. *** $P<0.001$ (one-way ANOVA, followed by Bonferroni post-hoc test). Data are expressed as mean \pm s.e.m.

to control levels (Fig. 6B). Together our results indicate that reducing levels of the TRPML1 agonist PI(3,5)P₂ induces an increase and enlargement of the endolysosomal compartments in neurons, similar to the endolysosomal pathology observed in LOAD hippocampal neurons (Fig. 1), and that this endolysosomal pathology can be remediated by ML-SA1 (Fig. 6B).

Inhibition of PIKfyve replicates AD-like enlargement of early endosomes that is rescued by the TRPML1 agonist ML-SA1

Early endosomal swelling has been reported repeatedly as a very early event in AD neuronal pathology (Cataldo et al., 2000; Decourt et al., 2013; Nixon et al., 2001) using several early endosome markers including EEA1, Rab4 (Rab4a and Rab4b) and Rab5. Furthermore, pathological Rab5 activation has been shown to mimic AD-like endosomal dysfunction (Pensalfini et al., 2020). We investigated whether YM201636 would also induce enlargement of early endosomes in primary neurons, and whether this could be rescued by ML-SA1 co-treatment, by measuring EEA1 immunopositive vesicle size automatically using CellProfiler. Vehicle treated early endosomes were on average $0.28\pm 0.013 \mu\text{m}^2$ (mean \pm s.e.m.). Incubation with YM201636 demonstrated a dose-dependent increase in EEA1 vesicle size to a maximum of $0.42\pm 0.019 \mu\text{m}^2$ (Fig. 7A). Notably, co-treatment with 4 μ M YM201636 and 50 μ M ML-SA1 rescued this AD-like early endosome enlargement partially by reducing the size of early endosomes to $0.35\pm 0.015 \mu\text{m}^2$ at 24 h (Fig. 7B).

Inhibition of PIKfyve leads to a dose-dependent accumulation of autophagic vesicles that can be rescued by the TRPML1 agonist, ML-SA1

The presence of various types of electron-dense autophagic vesicles (AVs) has been reported by us and others in post-mortem neocortex and hippocampus of AD cases (Boland et al., 2008; Bordi et al., 2016; Tang et al., 2015). We investigated whether inhibition of PIKfyve increases autophagy in rat primary cortical neurons by measuring levels of LC3-II (the lipidated form of MAP1LC3 family proteins), a marker of autophagic vesicles. After 6 h, treatment with 1 and 4 μ M YM201636, LC3-II levels increased slightly, whereas after 24 h a clear dose-dependent YM201636 (400 nM to 4 μ M) increase in LC3-II was observed (Fig. 7C). This was supported by immunofluorescence data showing a strong increase in LC3 foci in

primary neurons treated with 4 μ M YM201636 for 24 h (Fig. 7D). In concordance with the ability of TRPML1 activation to rescue early endosomal and endolysosomal AD-like EAL pathologies, ML-SA1 abolished the accumulation of LC3-positive autophagic puncta in rat primary cortical neurons (Fig. 7D). This was confirmed measuring total protein levels by western blot analysis (data not shown).

DISCUSSION

In this study, we demonstrate endolysosomal neuropathology in the brains of individuals who have had LOAD, indicative of functional defects in the endolysosomal TRPML1 Ca²⁺ channel. We further reveal a diminished ability of TRPML1 to release Ca²⁺, resulting in significant increases in endolysosomal Ca²⁺ in iPSC-derived human neurons expressing APOE $\epsilon 4$, the greatest risk factor for LOAD. Our results show that blocking the biosynthesis of PI(3,5)P₂, the endogenous agonist of TRPML1, in primary neurons by inhibiting PIKfyve, recreated TRPML1 endolysosomal neuropathology similar to that evident in LOAD neurons and APOE $\epsilon 4$ iPSC neurons. In addition, this treatment induced enlargement of early endosomes and the accumulation of autophagic vesicles, known to be central to EAL neuropathogenesis in AD. Finally, we demonstrate that the AD-like EAL neuropathology induced by PIKfyve inhibition can be remediated by treatment with ML-SA1, a small-molecule TRPML1 agonist. Together, these results highlight key defects in the TRPML1 endolysosomal system in AD pathogenesis and point to TRPML1 as a novel therapeutic target to remediate EAL neuropathogenesis in AD and related neurodegenerative disease.

TRPML1 is a master regulator of EAL health, whose malfunction causes neurodegeneration (Boudewyn and Walkley, 2019). Alterations in TRPML1 function have been associated with deletion of the PS-1 gene, implicating TRPML1 in FAD (Lee et al., 2015, 2010; Lie et al., 2022). However, little is known about TRPML1 function in LOAD. In our study, analysis of late endolysosomal health in LOAD hippocampal sections staged for AD severity implicates TRPML1 abnormalities in AD pathogenesis. We found levels of the endolysosomal marker LAMP1 are increased in CA1 and CA3 regions of AD hippocampi, and are enriched around senile plaques, consistent with previous analysis in the AD frontal cortex (Barrachina et al.,




Fig. 6. Enlargement of Rab7-positive endolysosomes is dose dependent for YM201636 and can be rescued by ML-SA1 co-treatment. (A) Representative images (left) and quantification (right) showing that depletion of PI(3,5)P₂ using 100 nM–4 μ M YM201636 in rat primary cortical neurons led to a dose-dependent increase in the size and intensity of Rab7-positive late endolysosomes. (B) Representative confocal images (left, top row), zoom (left, bottom row) and quantification (right) showing endolysosomal vacuolation and perinuclear accumulation of Rab7-positive vesicles, in rat primary cortical neurons after PIKfyve inhibition using 4 μ M YM201636, which is restored by co-treatment with 50 μ M ML-SA1. Quantitative data is based on four separate experiments with three images for each condition from two separate coverslips. veh, vehicle. Scale bars: 10 μ m (main images) and 2 μ m (magnifications). * P <0.05; ** P <0.01; *** P <0.001 (one-way ANOVA, followed by Bonferroni post-hoc test). Data are expressed as mean \pm s.e.m.

2006; Bordi et al., 2016; Piras et al., 2016). We demonstrate, for the first time to our knowledge, that there is a pronounced perinuclear clustering of endolysosomes in hippocampal AD neurons and, moreover, that a significant vacuolation of endolysosomal compartments is evident within CA3 cells with the phenotype of neurons in the AD brain. Increased perinuclear clustering of endolysosomes was also observed in GFAP-positive astrocytes in the AD hippocampus. Interestingly, studies indicate that TFEB function, a master regulator of lysosomal health, controlled by

TRPML1, is defective in astrocytes in the AD brain (Bordi et al., 2016; Grubman et al., 2019; Martini-Stoica et al., 2018).

The perinuclear accumulation of endolysosomes in AD hippocampi, including their vacuolation, resembles changes in endolysosomal morphology that occur upon decreased activation of TRPML1 (Dong et al., 2010; Zhang et al., 2012). In addition, inhibition of PIKfyve kinase activity, including via loss of function of FIG4 and Vac14, key components of the PIKfyve complex, depletes cells of the vital TRPML1 agonist PI(3,5)P₂. This causes a




Fig. 7. Enlargement of EEA1-positive endosomes and increase in autophagy are dose dependent for YM201636 and can be rescued by ML-SA1 co-treatment. (A,C) Representative images (left) and quantification (right) showing that depletion of PI(3,5)P₂ using 100 nM–4 μ M YM201636 (YM) in rat primary cortical neurons led to a dose-dependent increase in the size and intensity of early (EEA1) endosomes as well as to an accumulation of the autophagic marker LC3-II (C). Image in C representative of three repeats. (B,D) Representative confocal images (left) and quantification (right) showing early endosomal enlargement of EEA1-positive vesicles (B) and accumulation of LC3-II-positive autophagic vesicles (D) in rat primary cortical neurons after PIKfyve inhibition by 4 μ M YM201636, which is restored by co-treatment with 50 μ M ML-SA1. Scale bars: 10 μ m. Quantitative data is based on four separate experiments with three images for each condition from two separate coverslips. * P <0.05; ** P <0.01; *** P <0.001 (one-way ANOVA followed by Bonferroni post-hoc test). Data are expressed as mean \pm s.e.m.

number of defects in the endolysosomal system that are similar to those in MLIV, the most prominent of which is vacuolated endolysosomal compartments (Bissig et al., 2017; Chen et al., 2017; Choy et al., 2018; Dong et al., 2010; Edgar et al., 2020; Ikononov et al., 2002, 2001; Jefferies et al., 2008; Kim et al., 2014; Lines et al., 2017; Martin et al., 2013; McCartney et al., 2014; Zou et al., 2015).

Multiple risk genes for LOAD, including APOE $\epsilon 4$, play central roles in EAL function (Gao et al., 2018; Karch and Goate, 2015; Pimenova et al., 2018; Van Acker et al., 2019). Previous studies have shown that APOE $\epsilon 4$ -encoding alleles cause EAL enlargement, and endolysosomal trafficking impairments *in vivo* (Nuriel et al., 2017; Xian et al., 2018), indicative of TRPML1 dysfunction, but whether APOE $\epsilon 4$, the greatest genetic risk factor for LOAD, promotes TRPML1 defects was completely unknown. We found that APOE $\epsilon 4$ leads to a diminished Ca^{2+} release via TRPML1 in isogenic human iPSC-derived cortical neurons, resulting in significant accumulation of endolysosomal Ca^{2+} . These TRPML1-induced defects in endolysosomal Ca^{2+} handling were not accompanied by altered endolysosomal pH, indicating that endolysosomes in APOE $\epsilon 4$ neurons are not de-acidified. This was further indirectly verified by our finding that cathepsin D activity was increased in APOE $\epsilon 4$ neurons, in concordance with previous research showing increased cathepsin D levels in AD neurons (Cataldo et al., 1995, 1991). It is possible that endolysosomal levels of Fe^{2+} and Zn^{2+} , or their release from endolysosomes, could be altered due to the TRPML1 defects we describe in APOE $\epsilon 4$ neurons. We did not investigate this in detail; however, our results show no significant difference in endolysosomal Zn^{2+} levels when comparing the cortical neurons with differing APOE isoform expression. Studies that interrogate TRPML1 regulation of endolysosomal Fe^{2+} homeostasis in APOE $\epsilon 4$ cells and AD are an area deserving future investigation.

The pathological endolysosomal enlargement evident in AD neurons, which is also apparent in APOE $\epsilon 4$ -expressing cells (Nuriel et al., 2017; Xian et al., 2018), coupled with the disruption of TRPML1-mediated Ca^{2+} efflux that we describe here for the first time, supports the idea that there is an inability to effectively regulate lysosomal fusion–fission cycles, which are essential for regulation of lysosome number, size and function, in AD (Bissig et al., 2017; Li et al., 2016; Saffi and Botelho, 2019). In addition, this would be predicted to impact other key endolysosomal and autophagic functions that are regulated by TRPML1, as this endolysosomal Ca^{2+} channel maintains the dynamic homeostasis of the EAL system (reviewed in Di Paola and Medina, 2019; Di Paola et al., 2018; Huang et al., 2020; Li et al., 2019; Venkatachalam et al., 2015; Waller-Evans and Lloyd-Evans, 2015). Furthermore, recent studies show TRPML1 regulates broader cell functions, especially inter-organellar Ca^{2+} signalling (Kilpatrick et al., 2013). This includes regulation of mitochondrial Ca^{2+} dynamics (Calvo-Rodriguez et al., 2020; Jadiya et al., 2019) and ryanodine-receptor 2 (RyR2) Ca^{2+} release function (Thakore et al., 2020), which are known to be impaired in AD neurons (Chami and Checler, 2020; Kelliher et al., 1999; Lacampagne et al., 2017).

We were unable to obtain clear endolysosomal immunoreactivity with multiple LAMP1 antibodies in primary rat neurons and thus we employed the endolysosomal marker Rab7. LAMP1 is abundant on the lysosomal membrane and is most commonly used to label lysosomes (Wartosch et al., 2015). Rab7 is mechanistically important in membrane transport from the late endosome to the lysosome and is reported to label endolysosomal compartments where it shows a strong colocalization with LAMP1 (Bucci et al.,

2000; Guerra and Bucci, 2016; Humphries et al., 2011). Although LAMP1 and Rab7 colocalize in several endolysosomal compartments they can also label mutually exclusive membrane compartments, and the endolysosomal compartment in neurons has an added complexity (Lie et al., 2021). These considerations should be acknowledged when comparing our findings on endolysosomal integrity in the human brain and rat cortical neurons.

Here, we tested the hypothesis that depleting rat primary cortical neurons of $\text{PI}(3,5)\text{P}_2$, the TRPML1 agonist, by inhibiting PIKfyve kinase activity using the pharmacological inhibitor YM201636, would recreate the key EAL defects we detected in AD brain and in human neuronal APOE $\epsilon 4$ iPSCs. We found that PIKfyve inhibition increased endolysosomal Ca^{2+} levels to those we found in APOE $\epsilon 4$ -expressing neurons and was associated with the marked vacuolation of endolysosomal compartments. We further demonstrated that blocking PIKfyve activity induced a significant increase in the size of early endosomes in neurons. Notably, early endosomal swelling is a very early event in AD neuropathology (Cataldo et al., 2000; Decourt et al., 2013; Nixon et al., 2001). Finally, inhibiting neuronal PIKfyve activity significantly increased the number of LC3-positive autophagic puncta, which is in concordance with the presence of various types of electron-dense autophagic vesicles (AVs) reported in post-mortem neocortex and hippocampus of AD cases (Boland et al., 2008; Bordi et al., 2016; Tang et al., 2015).

Induction of these broad AD-like EAL defects in neurons by PIKfyve kinase inhibition has not been reported previously. However, recent studies found that loss of PIKfyve due to prion infection drives the spongiform neurodegeneration and neuronal vacuolation in prion disease, which can be rescued by $\text{PI}(3,5)\text{P}_2$ supplementation (Lakkaraju et al., 2021). Other recent work demonstrates that pharmacological inhibition of PIKfyve using YM201636 and apilimod reduces the trafficking of tau and α -synuclein from early endosomes to late endolysosomes, thus preventing fibril formation and implicating PIKfyve inhibition as neuroprotective in these *in vitro* models (See et al., 2021 preprint; Soares et al., 2021). However, the degree of EAL defects we demonstrate in neurons upon PIKfyve inhibition would advise caution in using PIKfyve inhibitors to protect against tau or α -synuclein fibrillization and spread in neurodegenerative disease, as also discussed by Lakkaraju et al. (2021). Collectively, these studies draw attention to the potential role of the PIKfyve complex in EAL defects in AD and other related neurodegenerative diseases. With respect to AD, it has been shown that the amyloid precursor protein (APP) binds to the PIKfyve complex and can regulate PIKfyve function and the formation of $\text{PI}(3,5)\text{P}_2$ (Balklava et al., 2015; Currinn et al., 2016). Endogenous levels of the low abundance $\text{PI}(3,5)\text{P}_2$, which localizes to the late endolysosome, cannot be detected with current mass spectrometry technology. However, our results show alterations in PI dynamics in AD brain, selectively affecting two PI species with broad functions in EAL trafficking and function, namely $\text{PI}(3,4,5)\text{P}_3$ and $\text{PI}(4,5)\text{P}_2$ (Balla, 2013; Botelho, 2009; Di Paolo and De Camilli, 2006; Vanhaesebroeck et al., 2012), the latter of which operates as the endogenous antagonist of TRPML1. Importantly, several LOAD risk genes were shown to regulate enzymes that control PI dynamics and interconversion (reviewed in Raghu et al., 2019), and altered PI composition has been reported previously in the LOAD brain (Morel et al., 2013; Stokes and Hawthorne, 1987; Zhu et al., 2015). Very recent research suggests that it is possible to achieve independent measurement of PIP_2 regioisomers, enabling measurement of $\text{PI}(3,5)\text{P}_2$ (Morioka et al., 2022). Achieving this should enable further understanding of mechanisms by which the dynamics of this vital low abundance phosphoinositide couples late endolysosomal

trafficking and function to TRPML1 activation in health and neurodegenerative disease.

Remarkably, we demonstrated for the first time that TRPML1 activation, via the small-molecule agonist ML-SA1 (Fine et al., 2020; Grimm et al., 2010; Shen et al., 2012), overrides the PI(3,5)P₂ deficit-induced defects caused by PIKfyve inhibition in neurons and protects against multiple AD-related EAL neuropathologies. In agreement, TRPML1-induced endolysosomal Ca²⁺ release ameliorated some endolysosomal defects when PIKfyve activity was inhibited in other cell types (Edgar et al., 2020; Li et al., 2016; Lines et al., 2017; Zou et al., 2015). Interestingly, here we demonstrated a much broader impact of ML-SA1 to remediate defects in EAL machinery induced by PIKfyve inhibition in primary neurons. Thus, ML-SA1 enabled normal Ca²⁺ release from endolysosomes and restored the size of lysosomal Ca²⁺ stores, diminished late (Rab7) and early (EEA1) endosomal enlargement and reduced the number of LC3-positive autophagic puncta. Taken together, these results highlight the mechanistic link between PIKfyve-PI(3,5)P₂ and TRPML1 in maintaining EAL neuronal health.

Interestingly, a protective effect of ML-SA1 has been demonstrated against α -synuclein toxicity in human dopaminergic neurons (Tsunemi et al., 2019), L-BMAA-induced neurodegeneration, modelling ALS, in primary neurons and in FIG4 deficiency linked to Charcot-Marie-Tooth disease (Edgar et al., 2020; Zou et al., 2015). These results suggest that ML-SA1 remediation of FIG4 deficiency and PIKfyve inhibition are mechanistically linked to activation of TRPML1-induced lysosomal fission. Furthermore, ML-SA1 cleared sphingomyelin and A β from LAMP1-positive lysosomes in an HIV cell model (Bae et al., 2014), and ML-SA1-induced acidification of endolysosomes blocked the LDL-induced increase in intra-neuronal and secreted levels of A β (Hui et al., 2019). Hui et al. further showed that antiretroviral drugs increase A β levels by de-acidifying endolysosomes, and that ML-SA1 prevented the resulting A β accumulation (Hui et al., 2021). Furthermore, TRPML1 activation is essential for TFEB-mediated regulation of lysosomal exocytosis, reducing tau pathology and spread in animal models (Xu et al., 2020).

Together, our study reveals that the TRPML1 agonist ML-SA1 reverses multiple key EAL abnormalities in primary neurons caused by PIKfyve inhibition that are similar to those described in AD neurons. These findings provide clear implications for our improved understanding of abnormalities in the EAL system in AD and other neurodegenerative diseases, highlight the mechanistic importance of TRPML1 endolysosomal Ca²⁺ signalling in these diseases and identify TRPML1 as a target for therapeutic intervention.

MATERIALS AND METHODS

Antibodies and reagents

The following antibodies were used for immunofluorescence: anti-EEA1 (BD Biosciences, USA, #610456, 1:400), anti-LAMP1 (D2D11) (Cell Signaling, USA, #9091, 1:50), anti-LAMP1 (H4A3) (Abcam, UK, ab25630 1:50); anti-LC3 (Cell Signaling, #2775, 1:250), anti-p-Ser396/404 tau (PHF1, a generous gift from Dr Peter Davies, Albert Einstein College of Medicine, NY, USA, 1:200), anti-Rab7 (Santa Cruz Biotechnology, USA, sc-376362, 1:100), anti-GFAP (DAKO, Z0334, 1:200), anti-TRPML1 [Sigma, HPA031763, batch 2 (2017) 1:10], goat-anti-mouse-IgG conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, USA, A11001, 1:400), donkey-anti-rabbit-IgG conjugated to Cy3 (Jackson Laboratories, USA, #711-165-152, 1:400). The following antibodies were used for western immunoblot analysis: anti-LAMP1 (H4A3) (Abcam, ab25630, 1:5000), anti-LC3 antibody (Cell Signaling, US, #2775, 1:1000), anti-TRPML1 [Sigma, HPA031763, batch 1 (2016) 1:250, batch 2 (2017) 1:1000], horse-anti-mouse-IgG conjugated to HRP (Cell Signaling, #7076, 1:1000) and goat

anti-rabbit-IgG conjugated to HRP (Cell Signaling, #7074, 1:1000). The following reagents were used: B27™ Supplement (Invitrogen), BODIPY-Pepstatin (Invitrogen, P12271), DNase1 (Sigma-Aldrich), FITC-dextran (Sigma-Aldrich, FD10S), Fluozin-3-AM (Invitrogen, F24195), Fura2-AM (Invitrogen), GlutaMAX™ (Invitrogen), Hank's balanced salt solution (HBSS) (Invitrogen), HEPES (Gibco, USA), ML-SA1 (Sigma-Aldrich, #SML0627), GW405833 (Sigma-Aldrich, #G1421), Neurobasal medium (Invitrogen, USA), Oregon Green™ 488 BAPTA-1, AM (Invitrogen, O6812), Pluronic™ F-127 (Sigma Aldrich, US, P2443), Poly-D-lysine (Sigma Aldrich, US), papain (Worthington, US), Pen/Strep (Invitrogen, US), sodium pyruvate (Invitrogen, US), Texas Red-dextran (Invitrogen, US, D1863), YM201636 (Invivogen, US, #INH-YM20).

Brain tissue

Brain tissue was provided by the Netherlands Brain Bank (NBB; see Table 1 for case details). Ethical approval and written informed consent from the donors or the next of kin was obtained in all cases (Griffin et al., 2005; Moloney et al., 2010) and all clinical investigation have been conducted according to the principles expressed in the Declaration of Helsinki. The work of the NBB abides by the ethical code of conduct approved by the Ethics committee and strict ethical guidelines as stated in Brain Net Europe Ethical Code of Conduct for brain banking (Klioueva et al., 2015). Clinical diagnosis of probable Alzheimer's disease was made according to the NINCDS-ADRDA criteria, and severity of dementia rated by the Global Deterioration Scale. Non-demented controls had no history or symptoms of neurological or psychiatric disorders. All cases were neuropathologically confirmed, using conventional histopathological techniques, and diagnosis performed using the CERAD criteria. Neuropathological staging of neurofibrillary changes (0–VI) was performed according to Braak and Braak (Braak and Braak, 1991). The degree of A β deposition in neuritic senile plaques was assessed in the temporal cortex, indicated as 0, A, B and C, for no, mild, moderate and high levels of senile plaques, respectively. Tissue fractions for western immunoblot and phosphoinositide analysis were prepared from AD and matched control mid-temporal cortex samples as described below. Brain tissue for immunofluorescence analysis was provided as formalin fixed and paraffin-embedded 8- μ m-thick consecutive sections prepared on Superfrost slides as previously described (Moloney et al., 2010). Control and AD tissue was matched for post-mortem delay, tissue pH, age, and agonal status as described previously (Griffin et al., 2005; Moloney et al., 2010). Western blot analysis using anti-TRPML1 batch 1 (2016) antibody was performed on brain tissue published previously in (Moloney et al., 2010) as well as tissue listed in Table 1.

Preparation of tissue fractions

Brain material for western immunoblotting was obtained as ~1 g frozen pieces, which were thawed, homogenised and fractionated. Tissue fractions were prepared as previously described (Griffin et al., 2005; Moloney et al., 2010). Briefly, membrane-enriched fractions (100,000 g pellet) were separated from the soluble cytosolic fractions (100,000 g supernatant) following centrifugation of tissue homogenates in a Beckman ultracentrifuge (type 42.1 rotor) at 100,000 g for 60 min at 4°C. Tissue fractions were stored at -70°C.

Human iPSC culture and neural differentiation

The isogenic APOE ϵ 2/ ϵ 2 (BIONi010-C-6), APOE ϵ 3/ ϵ 3 (BIONi010-C-2), APOE ϵ 4/ ϵ 4 (BIONi010-C-4) and APOE-null (BIONi010-C-3) iPSC lines were obtained from the EBiSC stem cell repository (<https://cells.ebisc.org>). iPSCs were cultured on vitronectin (Life Technologies)-coated six-well plates with E8 flex medium (Life Technologies) at 37°C and 5% CO₂. The medium was changed 1 day after plating and subsequently every other day until cells were 60–70% confluent. On the day of embryoid body (EB) formation, cells were washed once with PBS, treated with ReLeSR (Stem Cell Technologies, USA), collected as clumps, and transferred to a non-adherent dish where they were maintained overnight. The next day, EBs were washed with PBS and cultured on SLI medium, which contained advanced DMEM F-12 medium (ADF) supplemented with GlutaMAX™, penicillin and streptomycin (Life Technologies), 2% NeuroBrew 21 without retinoic acid (Miltenyi Biotec, Germany), the SMAD pathway inhibitors

LDN193189 (1 μ M, Stemgent, USA) and SB431542 (10 μ M, Abcam), and the WNT pathway inhibitor IWR1 (1.5 μ M) (Tocris, UK; Chambers et al., 2009). On day 6, the medium was replaced by SB431542- and LDN193189-containing medium without IWR1. On day 8, cells were treated with ReLeSR and plated onto a Matrigel (Corning, USA)-coated dish and cultured to day 16 in NMM medium [ADF with 2% Neuro Brew 21 with retinoic acid (Miltenyi Biotec) and 10 ng/ml FGF]. Neural progenitor cells were either frozen or further expanded.

Neuronal differentiation was initiated by seeding neuronal progenitor cells on a substrate of growth factor-reduced Matrigel and poly-L-lysine (Sigma-Aldrich) at a density of 10^5 cells/cm² and cultured for 7 days in SynaptoJuice A medium which contained ADF, 2% NeuroBrew 21 with retinoic acid, 2 μ M PD0332991 (Selleckchem, USA), 10 μ M DAPT (Sigma-Aldrich), 10 ng/ml BDNF (Miltenyi Biotec), 500 nM LM22A4 (Tocris), 10 μ M Forskolin (Tocris), 3 μ M CHIR99021 (Tocris), 300 μ M GABA (Sigma-Aldrich), 1.8 mM CaCl₂ (Sigma-Aldrich) and 200 mM ascorbic acid (Sigma-Aldrich). Half of the medium was refreshed every 2–3 days. After 7 days, the medium was replaced by SynaptoJuice B medium, which contained ADF and Neurobasal A medium in equal volume, 2% NeuroBrew 21 with retinoic acid, 2 μ M PD0332991, 10 ng/ml BDNF, 1.8 mM CaCl₂ and 200 mM ascorbic acid. Neurons were kept in SynaptoJuice B for up to 2 weeks, refreshing half the medium every 2–3 days. Extensive characterization of neurons obtained using this protocol has been published previously in various iPSC lines (Telezhkin et al., 2016). Cells were routinely monitored for mycoplasma and bacterial or yeast contaminations.

Primary cortical neuron culture

Primary cortical neurons were derived from embryonic day 18 wild-type Sprague-Dawley rat embryos as previously described (Boland et al., 2008). All animal experiments were performed according to approved guidelines. Single-cell suspensions obtained from cortices of individual embryos were plated on a poly-D-lysine-coated surface in neurobasal medium supplemented with 0.5 mM GlutaMAX™, 50 U/ml penicillin-streptomycin and 2% B27™ Supplement (50 \times). Cortical neurons were maintained at 37°C and 5% CO₂, with half of the plating medium being replaced every 3 days with neurobasal medium supplemented with 0.5 mM GlutaMAX™ and 2% B27 supplement (50 \times). Cortical neurons were cultured for 6 to 8 days *in vitro* (DIV6–8) before drug treatments were applied. Neurons were treated with YM201636 (Invivogen) or ML-SA1 (Sigma-Aldrich) diluted in neuronal medium for the time and concentration indicated in the results section. Cells were routinely monitored for bacterial or yeast contaminations.

Ca²⁺ measurements

Neuronal iPSCs were plated in 8-well chamber slides (Ibidi, Germany) and loaded with 1 μ M Fura-2-AM in culture medium containing 1% BSA at room temperature for 30–60 min, then washed with 1 \times HBSS with 10 mM HEPES, 1 mM MgCl₂ and 1 mM CaCl₂, left for 10 min to allow de-esterification of the Ca²⁺ dye, and imaged in 1 \times HBSS with 10 mM HEPES, 1 mM MgCl₂ and 50 μ M CaCl₂. Fluorescence was recorded using a Zeiss Axiovert 35 microscope with a CAIRN Optospin filter wheel, EXFO X-cite 120Pc light source and an ORCA-flash4.0 LT camera at two different excitation wavelengths (340 and 380 nm) and a single (495 nm) emission wavelength. Videos were recorded using the MetaFluor software (Molecular Device, Sunnyvale, CA, USA) and the ratio (F_{340}/F_{380}) was used to detect changes in intracellular [Ca²⁺] from whole-cell ROIs with background subtracted. Changes in cytoplasmic Ca²⁺ levels were recorded after addition of 2 μ M ionomycin (Calbiochem, USA) to clamp non-lysosomal stores followed by addition of 500 μ M GPN (AlfaAesar, USA) to release lysosomal Ca²⁺ or 200 nM bafilomycin A1 (Sigma-Aldrich) to activate TRPML1 via mild deacidification. Cells were pre-treated for 10 min with 10 μ M GW405833 (Sigma-Aldrich) for TRPML1 inhibition and 5 μ M xestospongine-C (Sigma Aldrich) for IP₃ receptor inhibition where needed. Cells were not pre-treated with ionomycin or xestospongine to record Ca²⁺ release via 10 μ M ML-SA1 alone, to capture the full physiological cellular response including subsequent Ca²⁺ release from other compartments. Ca²⁺ measurements on primary rat cortical neurons were carried out in a similar

fashion but using 5 μ M Fura-2-AM and an Olympus IX51 inverted fluorescence microscope equipped with a 75-W xenon arc lamp, an Optiscan monochromator (Cairn, Kent, UK), an Orca-ER charged-coupled device (CCD) camera (Hamamatsu Photonics, Hertfordshire, UK), and an Olympus UplanF1 1.3 NA 100 \times oil-immersion objective. Images were acquired and analysed with Andor iQ Bioimaging software version 1.9 (Andor, Belfast, UK) including subtracting of background by masking. *In situ* Ca²⁺ levels were measured as previously described (Lloyd-Evans et al., 2008), but using the cell-impermeant high molecular mass Ca²⁺-sensitive OGB (0.5 mg/ml) alongside Texas Red–dextran (0.1 mg/ml, not sensitive to Ca²⁺) as loading control (protocol adapted from Lelouvier and Puertollano, 2011 to measure lysosomal Ca²⁺). The ratio of green (OGB) to red (Texas Red–dextran) fluorescence, when calibrated against luminal pH, is indicative of the luminal Ca²⁺ concentration in endolysosomes.

Lysosomal pH assay

Neurons were loaded with 500 μ g/ml pH-sensitive FITC–dextran (10,000 kDa) and 250 μ g/ml Texas Red–dextran (10,000 kDa, non-pH-sensitive loading control) in 1:1 Advanced DMEM/F12 (with GlutaMax™); Neurobasal A (Life Technologies), 1% penicillin/streptomycin (Life Technologies), 2% NeuroBrew21 with Retinoic Acid (Miltenyi Biotec), 0.3 mM CaCl₂ (to give 1.8 mM CaCl₂ in final complete medium; Sigma-Aldrich) and 200 μ M ascorbic acid (Sigma-Aldrich) for 24 h. Then dextran medium was removed, and cells were washed in fresh medium and incubated for a further 24 h in fresh medium. The medium was removed, and nuclei stained with Hoechst 33342 (1 μ g/ml in warmed HBSS; Sigma-Aldrich) for 10 min, washed in HBSS and imaged using a Perkin Elmer Operetta high content imaging system. To determine the ratio of FITC/Texas Red fluorescence, cells were first identified using the Hoechst 33342 staining (352 nm/454 nm). Texas Red-positive vesicles within the cell body were identified, and fluorescence intensity for both Texas Red (586 nm/603 nm) and FITC (491 nm/516 nm) was measured within each vesicle. The FITC/Texas Red ratio was calculated for each vesicle and averaged per well. Three plates with two wells per plate were imaged for each *APOE* genotype.

Subcellular distribution of cathepsin D

The subcellular distribution of processed active cathepsin D was analysed using BODIPY-pepstatin (Invitrogen) following the manufacturer's instructions, but at a 1:500 dilution and incubating for 15 min at 37°C followed by three washes in Dulbecco's PBS (DPBS). Images were taken and analysed using a Perkin Elmer Operetta high content imaging system.

Zn²⁺ measurement

Cells were stained with 5 μ M FluoZin-3-AM (Invitrogen) [in SynaptoJuice B containing 0.0025% pluronic acid F127 (Sigma-Aldrich) dissolved in DMSO] for 30 min at 37°C. Cells were washed twice and imaged in HBSS containing 1 mM CaCl₂, 1 mM MgCl₂ and 5 mM HEPES (pH 7.2). Images were taken on the Colibri LED microscope system at 470 nm (excitation)/510 nm (emission) or Perkin Elmer Operetta high-content imaging system.

Western immunoblot analysis

A BCA protein assay (Millipore) was used for protein measurements. Cell and tissue extracts were run on 8–16% Tris-glycine gels in Tris-glycine running buffer and transferred onto 0.2 μ m nitrocellulose membranes. LiCor total protein stain (LI-COR, USA) was used to ensure equality of protein loading and is presented in Fig. S4. After blocking in 5% non-fat milk or 5% BSA, membranes were processed for immunoblotting. Immunodetection was obtained using ECL reagent (GE Healthcare, USA) and developed using Fujifilm X-ray film.

Immunofluorescence of brain sections

Immunofluorescence analysis was performed as described previously (Moloney et al., 2010). Briefly, sections were deparaffinised and hydrated prior to microwave pre-treatment (30 min in 10 mM citrate buffer pH 6.4). After cooling, nonspecific binding was blocked using 5% normal donkey serum (Sigma-Aldrich) in PBS pH 7.4 for 30 min at room temperature, followed by overnight incubation with primary antibodies in blocking buffer. Slides were

then incubated in secondary antibodies diluted in blocking buffer for 1 h at room temperature in the dark. Nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI; 1.25 µg/ml) (Sigma-Aldrich). To lower the intensity of lipofuscin auto-fluorescence, slides were finally incubated for 10 min with 0.1% Sudan Black B (Sigma-Aldrich) in 70% ethanol, washed with 1× PBS and mounted using fluorescence mounting medium (DAKO, USA). Images were visualised on a Leica DMI 3000B inverted fluorescence microscope and captured using a Leica DFC420C digital camera, and on an Olympus FluoView FV10i. Confocal images were captured on an inverted Zeiss LSM 510 Meta confocal microscope, using a PlanApo 63×1.6 N/A oil immersion objective. Images were processed using ImageJ/Imaris 7.2 (Bitplane, CH).

Immunofluorescence of primary neuronal cultures

Cells were fixed (4% paraformaldehyde, 15 min, RT or MeOH, 10 min, −20°C), quenched (50 mM NH₄Cl, 15 min, room temperature) and permeabilized (0.3% Triton-X-100 in 1% BSA-PBS, 10 min, room temperature) for indirect immunofluorescence. Incubation with primary antibodies in blocking solution (5% BSA-PBS, 2 h, room temperature) was followed by a 1 h incubation with Alexa Fluor-488- or Cy3-conjugated secondary antibodies (in 5% BSA-PBS, room temperature) and mounting in Mowiol. Images were captured using a Zeiss LSM 510 Meta confocal microscope system and oil-immersion Plan-Apochromat 63× A/1.40 NA objective lenses. Data were collected using Zeiss ZEN software and processed in ImageJ. Quantitative Rab7, EEA1 and LC3 data is based on four separate experiments with three images for each condition from two separate coverslips (24 images per treatment).

Mass spectrometry analysis of phosphoinositide levels

Mass spectrometry was used to measure phosphoinositide lipid levels essentially as previously described (Furlong et al., 2019; Kielkowska et al., 2014), using a QTRAP 4000 (AB Sciex) mass spectrometer and employing the lipid extraction and derivatization method described for whole tissue (temporal cortex 0.5 mg wet weight ground tissue), with the modification that 10 ng C17:0/C16:0 PI(3,4,5)P₃ internal standard (ISD) and 10 ng C17:0/C16:0 PI ISD were added to primary extracts. Measurements were conducted for $n=12$ for human temporal cortex samples of AD patients and controls (Table 1). PIP, PIP₂ and PIP₃ response ratios were calculated by dividing the total PIP, PIP₂ and PIP₃ response areas for the most abundant molecular species present [C38:4+C38:3] in the cortex by the corresponding response areas of the PIP₂-ISD (for PIP and PIP₂) and PIP₃-ISD (PIP₃ only) in each sample. PI response ratios were calculated by dividing PI response areas by the response area for the PI-ISD. PIP, PIP₂, and PIP₃ response ratios were then normalised to the PI response ratio to account for any cell input variability. In some experiments, C38:4-PI(3,4)P₂ and C38:4-PI(4,5)P₂ regioisomers were distinguished and quantified in parallel ground cortex samples (0.5 mg wet weight), employing previously described methods (Malek et al., 2017).

Statistical analysis

Data are expressed as means±s.e.m. and statistics are based on at least $n=3$ (biological replicates) if not stated otherwise. Significance levels for comparisons between two groups were determined using an unpaired two-tailed Student's *t*-test. Significance levels for comparisons between more than two groups were determined using one-way ANOVA, followed by the Bonferroni post-hoc test. A *P*-value of 0.05 was considered as the borderline for statistical significance. GraphPad Prism™ 8 and Microsoft Excel software were used for statistical analysis and generation of graphs. Significance is denoted as **P*<0.05; ***P*<0.01; ****P*<0.001.

Acknowledgements

The authors would like to thank our colleagues at the Netherlands Brain Bank, particularly Michiel Kooreman. We gratefully acknowledge Mary McCaffrey for access to the Zeiss LSM 510 Meta confocal microscope funded by SFI program grants (02/IN1/B070; 05/IN3/B763). The authors are grateful to the funding agencies who supported this work, these are listed below.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: A.S., R.S., B.B., C.O.; Methodology: A.S., E.L.-E., N.D.A., J.J.M., J.W., K.E.A., P.T.H., S.E.G., H.W.-E., B.B., C.O.; Validation: A.S., E.L.-E., B.B., C.O.; Formal analysis: A.S., E.L.-E., S.E.G., H.W.-E., K.E.A.; Investigation: A.S., E.D.K., K.E.A., S.E.G., H.W.-E.; Resources: E.L.-E., N.D.A., R.S., E.L.-E., B.B., C.O.; Data curation: A.S., E.L.-E., B.B., C.O.; Writing - original draft: A.S., C.O.; Writing - review & editing: A.S., E.L.-E., B.B., C.O.; Visualization: A.S., E.L.-E., S.E.G., H.W.-E.; Supervision: E.L.-E., B.B., C.O.; Project administration: E.L.-E., R.S., B.B., C.O.; Funding acquisition: B.B., C.O., R.S.

Funding

This research was funded by the Science Foundation Ireland (SFI) and the Medical Research Council (MRC) UK with the Network of Centres of Excellence in Neurodegeneration (CoEN) Pathfinder II (SFI15/COEN/3037). P.T.H. and K.E.A. were funded by Biotechnology and Biological Sciences Research Council (BBSRC) UK (BB/J004456/1 and BB/P013384/1). Funding for E.D.K. and E.L.-E. was from Alzheimer's Research UK (grant number ARUK-IRG2015-7) alongside support for items of the Ca²⁺ imaging rigs from the local ARUK network. H.W.-E. and S.E.G. were funded by BRACE Dementia Research (grant number BR2240). N.D.A. was funded by Wales Gene Park (HCRW RD12020). Open access funding provided by University College Cork. Deposited in PMC for immediate release.

Data availability

All relevant data can be found within the article and its supplementary information.

Peer review history

The peer review history is available online at <https://journals.biologists.com/jcs/lookup/doi/10.1242/jcs.259875.reviewer-comments.pdf>

References

- Akwa, Y., Di Malta, C., Zallo, F., Gondard, E., Lunati, A., Diaz-De-Grenu, L. Z., Zampelli, A., Boiret, A., Santamaria, S., Martinez-Preciado, M. et al. (2023). Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies. *Autophagy* **19**, 660-677. doi:10.1080/15548627.2022.2095791
- Bae, M., Patel, N., Xu, H., Lee, M., Tominaga-Yamanaka, K., Nath, A., Geiger, J., Gorospe, M., Mattson, M. P. and Haughey, N. J. (2014). Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection. *J. Neurosci.* **34**, 11485-11503. doi:10.1523/JNEUROSCI.0210-14.2014
- Balklava, Z., Niehage, C., Currinn, H., Mellor, L., Guscott, B., Poulin, G., Hoflack, B. and Wassmer, T. (2015). The amyloid precursor protein controls PIKfyve function. *PLoS One* **10**, e0130485. doi:10.1371/journal.pone.0130485
- Balla, T. (2013). Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol. Rev.* **93**, 1019-1137. doi:10.1152/physrev.00028.2012
- Bargal, R., Avidan, N., Olender, T., Ben Asher, E., Zeigler, M., Raas-Rothschild, A., Frumkin, A., Ben-Yoseph, O., Friedlander, Y., Lancet, D. et al. (2001). Mucopolidiosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population. *Hum. Mutat.* **17**, 397-402. doi:10.1002/humu.1115
- Barrachina, M., Maes, T., Buesa, C. and Ferrer, I. (2006). Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* **32**, 505-516. doi:10.1111/j.1365-2990.2006.00756.x
- Bassi, M. T., Manzoni, M., Monti, E., Pizzo, M. T., Ballabio, A. and Borsani, G. (2000). Cloning of the gene encoding a novel integral membrane protein, mucopolidiosis type IV. *Am. J. Hum. Genet.* **67**, 1110-1120. doi:10.1016/S0002-9297(07)62941-3
- Bergling, S., Dolmetsch, R., Lewis, R. S. and Keizer, J. (1998). A fluorometric method for estimating the calcium content of internal stores. *Cell Calcium* **23**, 251-259. doi:10.1016/s0143-4160(98)90123-3
- Bissig, C., Hurbain, I., Raposo, G. and Van Niel, G. (2017). PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes. *Traffic* **18**, 747-757. doi:10.1111/tra.12525
- Boland, B., Kumar, A., Lee, S., Platt, F. M., Wegiel, J., Yu, W. H. and Nixon, R. A. (2008). Autophagy induction and autophagosomal clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J. Neurosci.* **28**, 6926-6937. doi:10.1523/JNEUROSCI.0800-08.2008
- Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchon, M. R. et al. (2018). Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nat. Rev. Drug Discov.* **17**, 660-688. doi:10.1038/nrd.2018.109
- Bordi, M., Berg, M. J., Mohan, P. S., Peterhoff, C. M., Alldred, M. J., Che, S., Ginsberg, S. D. and Nixon, R. A. (2016). Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy. *Autophagy* **12**, 2467-2483. doi:10.1080/15548627.2016.1239003

- Botelho, R. J.** (2009). Changing phosphoinositides "on the fly": how trafficking vesicles avoid an identity crisis. *BioEssays* **31**, 1127-1136. doi:10.1002/bies.200900060
- Boudewyn, L. C. and Walkley, S. U.** (2019). Current concepts in the neuropathogenesis of mucopolidosis type IV. *J. Neurochem.* **148**, 669-689. doi:10.1111/jnc.14462
- Bozym, R. A., Thompson, R. B., Stoddard, A. K. and Fierke, C. A.** (2006). Measuring picomolar intracellular exchangeable zinc in PC-12 cells using a ratiometric fluorescence biosensor. *ACS Chem. Biol.* **1**, 103-111. doi:10.1021/cb500043a
- Bozym, R. A., Chimienti, F., Giblin, L. J., Gross, G. W., Korichneva, I., Li, Y., Libert, S., Maret, W., Parviz, M., Frederickson, C. J. et al.** (2010). Free zinc ions outside a narrow concentration range are toxic to a variety of cells in vitro. *Exp. Biol. Med. (Maywood)* **235**, 741-750. doi:10.1258/ebm.2010.009258
- Braak, H. and Braak, E.** (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* **82**, 239-259. doi:10.1007/BF00308809
- Bucci, C., Thomsen, P., Nicoziani, P., Mccarthy, J. and Van Deurs, B.** (2000). Rab7: a key to lysosome biogenesis. *Mol. Biol. Cell* **11**, 467-480. doi:10.1091/mbc.11.2.467
- Cai, X., Xu, Y., Cheung, A. K., Tomlinson, R. C., Alcazar-Roman, A., Murphy, L., Billich, A., Zhang, B., Feng, Y., Klumpp, M. et al.** (2013). PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. *Chem. Biol.* **20**, 912-921. doi:10.1016/j.chembiol.2013.05.010
- Calvo-Rodriguez, M., Hou, S. S., Snyder, A. C., Kharitonova, E. K., Russ, A. N., Das, S., Fan, Z., Muzikansky, A., Garcia-Alloza, M., Serrano-Pozo, A. et al.** (2020). Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. *Nat. Commun.* **11**, 2146. doi:10.1038/s41467-020-16074-2
- Campeau, P. M., Lenk, G. M., Lu, J. T., Bae, Y., Burrage, L., Turnpenny, P., Roman Corona-Rivera, J., Morandi, L., Mora, M., Reutter, H. et al.** (2013). Yunis-Varon syndrome is caused by mutations in FIG4, encoding a phosphoinositide phosphatase. *Am. J. Hum. Genet.* **92**, 781-791. doi:10.1016/j.ajhg.2013.03.020
- Cao, Q., Yang, Y., Zhong, X. Z. and Dong, X. P.** (2017). The lysosomal Ca(2+) release channel TRPML1 regulates lysosome size by activating calmodulin. *J. Biol. Chem.* **292**, 8424-8435. doi:10.1074/jbc.M116.772160
- Cataldo, A. M., Paskovich, P. A., Kominami, E. and Nixon, R. A.** (1991). Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. *Proc. Natl. Acad. Sci. USA* **88**, 10998-11002. doi:10.1073/pnas.88.24.10998
- Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lipka, C. and Nixon, R. A.** (1995). Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. *Neuron* **14**, 671-680. doi:10.1016/0896-6273(95)90324-0
- Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T. and Nixon, R. A.** (2000). Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and down syndrome. *Am. J. Pathol.* **157**, 277-286. doi:10.1016/S0002-9440(10)64538-5
- Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M. and Studer, L.** (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* **27**, 275-280. doi:10.1038/nbt.1529
- Chami, M. and Checler, F.** (2020). Targeting post-translational remodeling of ryanodine receptor: a new track for Alzheimer's disease therapy? *Curr. Alzheimer Res.* **17**, 313-323. doi:10.2174/1567205017666200225102941
- Chen, C. S., Chen, W. N., Zhou, M., Arttamangkul, S. and Haugland, R. P.** (2000). Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy. *J. Biochem. Biophys. Methods* **42**, 137-151. doi:10.1016/S0165-022X(00)00048-8
- Chen, C. C., Butz, E. S., Chao, Y. K., Grishchuk, Y., Becker, L., Heller, S., Slaugenhaupt, S. A., Biel, M., Wahl-Schott, C. and Grimm, C.** (2017). Small molecules for early endosome-specific patch clamping. *Cell Chem Biol* **24**, 907-916.e4. doi:10.1016/j.chembiol.2017.05.025
- Cheng, X., Shen, D., Samie, M. and Xu, H.** (2010). Mucopolipins: intracellular TRPML1-3 channels. *FEBS Lett.* **584**, 2013-2021. doi:10.1016/j.febslet.2009.12.056
- Chow, C. Y., Zhang, Y., Dowling, J. J., Jin, N., Adamska, M., Shiga, K., Szigeti, K., Shy, M. E., Li, J., Zhang, X. et al.** (2007). Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. *Nature* **448**, 68-72. doi:10.1038/nature05876
- Chow, C. Y., Landers, J. E., Bergren, S. K., Sapp, P. C., Grant, A. E., Jones, J. M., Everett, L., Lenk, G. M., McKenna-Yasek, D. M., Weisman, L. S. et al.** (2009). Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am. J. Hum. Genet.* **84**, 85-88. doi:10.1016/j.ajhg.2008.12.010
- Choy, C. H., Saffi, G., Gray, M. A., Wallace, C., Dayam, R. M., Ou, Z. A., Lenk, G., Puertollano, R., Watkins, S. C. and Botelho, R. J.** (2018). Lysosome enlargement during inhibition of the lipid kinase PIKfyve proceeds through lysosome coalescence. *J. Cell Sci.* **131**, jcs213587. doi:10.1242/jcs.213587
- Condello, C., Schain, A. and Grutzendler, J.** (2011). Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. *Sci. Rep.* **1**, 19. doi:10.1038/srep00019
- Curriñ, H., Guscott, B., Balklava, Z., Rothnie, A. and Wassmer, T.** (2016). APP controls the formation of PI(3,5)P(2) vesicles through its binding of the PIKfyve complex. *Cell. Mol. Life Sci.* **73**, 393-408. doi:10.1007/s00018-015-1993-0
- De Leo, M. G., Staiano, L., Vicinanza, M., Luciani, A., Carissimo, A., Mutarelli, M., Di Campi, A., Polishchuk, E., Di Tullio, G., Morra, V. et al.** (2016). Autophagosome-lysosome fusion triggers a lysosomal response mediated by TLR9 and controlled by OCRL. *Nat. Cell Biol.* **18**, 839-850. doi:10.1038/ncb3386
- Decourt, B., Gonzales, A., Beach, T. G., Malek-Ahmadi, M., Walker, A., Sue, L., Walker, D. G. and Sabbagh, M. N.** (2013). BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. *Curr. Alzheimer Res.* **10**, 309-315. doi:10.2174/1567205011310030010
- Di Paolo, G. and De Camilli, P.** (2006). Phosphoinositides in cell regulation and membrane dynamics. *Nature* **443**, 651-657. doi:10.1038/nature05185
- Di Paola, S. and Medina, D. L.** (2019). TRPML1-TFEB-Dependent Regulation of Lysosomal Exocytosis. *Methods Mol. Biol.* **1925**, 143-144. doi:10.1007/978-1-4939-9018-4_12
- Di Paola, S., Scotto-Rosato, A. and Medina, D. L.** (2018). TRPML1: the Ca(2+)retaker of the lysosome. *Cell Calcium* **69**, 112-121. doi:10.1016/j.ceca.2017.06.006
- Dong, X. P., Cheng, X., Mills, E., Delling, M., Wang, F., Kurz, T. and Xu, H.** (2008). The type IV mucopolidosis-associated protein TRPML1 is an endolysosomal iron release channel. *Nature* **455**, 992-996. doi:10.1038/nature07311
- Dong, X. P., Shen, D., Wang, X., Dawson, T., Li, X., Zhang, Q., Cheng, X., Zhang, Y., Weisman, L. S., Delling, M. et al.** (2010). PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome. *Nat. Commun.* **1**, 38. doi:10.1038/ncomms1037
- Edgar, J. R., Ho, A. K., Laura, M., Horvath, R., Reilly, M. M., Luzio, J. P. and Roberts, R. C.** (2020). A dysfunctional endolysosomal pathway common to two sub-types of demyelinating Charcot-Marie-Tooth disease. *Acta Neuropathol. Commun.* **8**, 165. doi:10.1186/s40478-020-01043-z
- Feng, X., Huang, Y., Lu, Y., Xiong, J., Wong, C. O., Yang, P., Xia, J., Chen, D., Du, G., Venkatachalam, K. et al.** (2014a). Drosophila TRPML forms PI(3,5)P2-activated cation channels in both endolysosomes and plasma membrane. *J. Biol. Chem.* **289**, 4262-4272. doi:10.1074/jbc.M113.506501
- Feng, X., Xiong, J., Lu, Y., Xia, X. and Zhu, M. X.** (2014b). Differential mechanisms of action of the mucolipin synthetic agonist, ML-SA1, on insect TRPML and mammalian TRPML1. *Cell Calcium* **56**, 446-456. doi:10.1016/j.ceca.2014.09.004
- Fine, M., Schmiede, P. and Li, X.** (2018). Structural basis for PtdInsP2-mediated human TRPML1 regulation. *Nat. Commun.* **9**, 4192. doi:10.1038/s41467-018-06493-7
- Fine, M., Li, X. and Dang, S.** (2020). Structural insights into group II TRP channels. *Cell Calcium* **86**, 102107. doi:10.1016/j.ceca.2019.102107
- Funk, K. E., Mrak, R. E. and Kuret, J.** (2011). Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late-stage autophagic organelles. *Neuropathol. Appl. Neurobiol.* **37**, 295-306. doi:10.1111/j.1365-2990.2010.01135.x
- Furlong, R. M., Lindsay, A., Anderson, K. E., Hawkins, P. T., Sullivan, A. M. and O'Neill, C.** (2019). The Parkinson's disease gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P3. *J. Cell Sci.* **132**, jcs233221. doi:10.1242/jcs.233221
- Gao, S., Casey, A. E., Sargeant, T. J. and Mäkinen, V. P.** (2018). Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease. *Brain* **141**, 2711-2720. doi:10.1093/brain/awy197
- Gerasimenko, J. V., Tepikin, A. V., Petersen, O. H. and Gerasimenko, O. V.** (1998). Calcium uptake via endocytosis with rapid release from acidifying endosomes. *Curr. Biol.* **8**, 1335-1338. doi:10.1016/S0960-9822(07)00565-9
- Ginsberg, S. D., Mufson, E. J., Counts, S. E., Wu, J., Alldred, M. J., Nixon, R. A. and Che, S.** (2010). Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. *J. Alzheimers Dis.* **22**, 631-639. doi:10.3233/JAD-2010-101080
- Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P. and Ferguson, S. M.** (2015). Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. *Proc. Natl. Acad. Sci. USA* **112**, E3699-E3708. doi:10.1073/pnas.1510329112
- Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'connor, R. and O'Neill, C.** (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J. Neurochem.* **93**, 105-117. doi:10.1111/j.1471-4159.2004.02949.x
- Grimm, C., Jors, S., Saldanha, S. A., Obukhov, A. G., Pan, B., Oshima, K., Cuajungco, M. P., Chase, P., Hodder, P. and Heller, S.** (2010). Small molecule activators of TRPML3. *Chem. Biol.* **17**, 135-148. doi:10.1016/j.chembiol.2009.12.016
- Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, X. Y., Mclean, C., Simmons, R. K., Buckberry, S., Vargas-Landin, D. B., Poppe, D. et al.** (2019). A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease

- reveals cell-type-specific gene expression regulation. *Nat. Neurosci.* **22**, 2087-2097. doi:10.1038/s41593-019-0539-4
- Guerra, F. and Bucci, C.** (2016). Multiple roles of the small GTPase Rab7. *Cells* **5**, 34. doi:10.3390/cells5030034
- Hille, B., Dickson, E. J., Kruse, M., Vivas, O. and Suh, B. C.** (2015). Phosphoinositides regulate ion channels. *Biochim. Biophys. Acta* **1851**, 844-856. doi:10.1016/j.bbali.2014.09.010
- Huang, P., Xu, M., Wu, Y., Rizvi Syeda, A. K. and Dong, X. P.** (2020). Multiple facets of TRPML1 in autophagy. *Cell Calcium* **88**, 102196. doi:10.1016/j.ceca.2020.102196
- Hui, L., Soliman, M. L., Geiger, N. H., Miller, N. M., Afghah, Z., Lakpa, K. L., Chen, X. and Geiger, J. D.** (2019). Acidifying endolysosomes prevented low-density lipoprotein-induced amyloidogenesis. *J. Alzheimers Dis.* **67**, 393-410. doi:10.3233/JAD-180941
- Hui, L., Ye, Y., Soliman, M. L., Lakpa, K. L., Miller, N. M., Afghah, Z., Geiger, J. D. and Chen, X.** (2021). Antiretroviral drugs promote amyloidogenesis by deacidifying endolysosomes. *J. Neuroimmune Pharmacol.* **16**, 159-168. doi:10.1007/s11481-019-09862-1
- Humphries, W. H., Szymanski, C. J. and Payne, C. K.** (2011). Endo-lysosomal vesicles positive for Rab7 and LAMP1 are terminal vesicles for the transport of dextran. *PLoS One* **6**, e26626. doi:10.1371/journal.pone.0026626
- Hung, C. O. Y. and Livesey, F. J.** (2018). Altered gamma-secretase processing of APP disrupts lysosome and autophagosomal function in monogenic Alzheimer's disease. *Cell Rep.* **25**, 3647-3660.e2. doi:10.1016/j.celrep.2018.11.095
- Ikonomov, O. C., Sbrissa, D. and Shisheva, A.** (2001). Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve. *J. Biol. Chem.* **276**, 26141-26147. doi:10.1074/jbc.M101722200
- Ikonomov, O. C., Sbrissa, D., Mlak, K., Kanzaki, M., Pessin, J. and Shisheva, A.** (2002). Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of PtdIns 3,5-P2 production for endomembrane integrity. *J. Biol. Chem.* **277**, 9206-9211. doi:10.1074/jbc.M108750200
- Jadiya, P., Kolmetzky, D. W., Tomar, D., Di Meco, A., Lombardi, A. A., Lambert, J. P., Luongo, T. S., Ludtmann, M. H., Pratico, D. and Elrod, J. W.** (2019). Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. *Nat. Commun.* **10**, 3885. doi:10.1038/s41467-019-11813-6
- Jefferies, H. B., Cooke, F. T., Jat, P., Boucheron, C., Koizumi, T., Hayakawa, M., Kaizawa, H., Ohishi, T., Workman, P., Waterfield, M. D. et al.** (2008). A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. *EMBO Rep.* **9**, 164-170. doi:10.1038/sj.embor.7401155
- Kandalepas, P. C., Sadleir, K. R., Eimer, W. A., Zhao, J., Nicholson, D. A. and Vassar, R.** (2013). The Alzheimer's β -secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. *Acta Neuropathol.* **126**, 329-352. doi:10.1007/s00401-013-1152-3
- Karch, C. M. and Goate, A. M.** (2015). Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol. Psychiatry* **77**, 43-51. doi:10.1016/j.biopsych.2014.05.006
- Kelliher, M., Fastbom, J., Cowburn, R. F., Bonkale, W., Ohm, T. G., Ravid, R., Sorrentino, V. and O'Neill, C.** (1999). Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and β -amyloid pathologies. *Neuroscience* **92**, 499-513. doi:10.1016/S0306-4522(99)00042-1
- Kendall, R. L. and Holian, A.** (2021). The role of lysosomal ion channels in lysosome dysfunction. *Inhal. Toxicol.* **33**, 41-54. doi:10.1080/08958378.2021.1876188
- Kielkowska, A., Niewczalas, I., Anderson, K. E., Durrant, T. N., Clark, J., Stephens, L. R. and Hawkins, P. T.** (2014). A new approach to measuring phosphoinositides in cells by mass spectrometry. *Adv. Biol. Regul.* **54**, 131-141. doi:10.1016/j.jbior.2013.09.001
- Kilpatrick, B. S., Eden, E. R., Schapira, A. H., Futter, C. E. and Patel, S.** (2013). Direct mobilisation of lysosomal Ca²⁺ triggers complex Ca²⁺ signals. *J. Cell Sci.* **126**, 60-66. doi:10.1242/jcs.118836
- Kim, G. H., Dayam, R. M., Prashar, A., Terebiznik, M. and Botelho, R. J.** (2014). PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages. *Traffic* **15**, 1143-1163. doi:10.1111/tra.12199
- Kiselyov, K., Colletti, G. A., Terwilliger, A., Ketchum, K., Lyons, C. W., Quinn, J. and Muallem, S.** (2011). TRPML: transporters of metals in lysosomes essential for cell survival? *Cell Calcium* **50**, 288-294. doi:10.1016/j.ceca.2011.04.009
- Klioueva, N. M., Rademaker, M. C., Dexter, D. T., Al-Sarraj, S., Seilhean, D., Streichenberger, N., Schmitz, P., Bell, J. E., Ironside, J. W. et al.** (2015). BrainNet Europe's Code of Conduct for brain banking. *J. Neural Transm.* **122**, 937-940. doi:10.1007/s00702-014-1353-5
- Kohler, C.** (2016). Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. *Acta Neuropathol.* **132**, 339-359. doi:10.1007/s00401-016-1562-0
- Krezel, A. and Maret, W.** (2006). Zinc-buffering capacity of a eukaryotic cell at physiological pZn. *J. Biol. Inorg. Chem.* **11**, 1049-1062. doi:10.1007/s00775-006-0150-5
- Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M., Fak, J., Olsen, O., Darnell, R. B. and Tessier-Lavigne, M.** (2019). A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β -CTFs, Not $\text{A}\beta$. *Neuron* **104**, 1022. doi:10.1016/j.neuron.2019.11.010
- Lacampagne, A., Liu, X., Reiken, S., Bussiere, R., Meli, A. C., Lauritzen, I., Teich, A. F., Zalk, R., Saint, N., Arancio, O. et al.** (2017). Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like pathologies and cognitive deficits. *Acta Neuropathol.* **134**, 749-767. doi:10.1007/s00401-017-1733-7
- Lakkaraju, A. K. K., Frontzek, K., Lemes, E., Herrmann, U., Losa, M., Marpakwar, R. and Aguzzi, A.** (2021). Loss of PIKfyve drives the spongiform degeneration in prion diseases. *EMBO Mol. Med.* **13**, e14714.
- Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G. et al.** (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* **141**, 1146-1158. doi:10.1016/j.cell.2010.05.008
- Lee, J. H., Mcbrayer, M. K., Wolfe, D. M., Haslett, L. J., Kumar, A., Sato, Y., Lie, P. P., Mohan, P., Coffey, E. E., Kompella, U. et al.** (2015). Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. *Cell Rep.* **12**, 1430-1444. doi:10.1016/j.celrep.2015.07.050
- Lelouvier, B. and Puertollano, R.** (2011). Mucopolipin-3 regulates luminal calcium, acidification, and membrane fusion in the endosomal pathway. *J. Biol. Chem.* **286**, 9826-9832. doi:10.1074/jbc.M110.169185
- Li, R. J., Xu, J., Fu, C., Zhang, J., Zheng, Y. G., Jia, H. and Liu, J. O.** (2016). Regulation of mTORC1 by lysosomal calcium and calmodulin. *Elife* **5**, e19360. doi:10.7554/eLife.19360
- Li, M., Zhang, W. K., Benvin, N. M., Zhou, X., Su, D., Li, H., Wang, S., Michailidis, I. E., Tong, L., Li, X. et al.** (2017). Structural basis of dual Ca(2+)/pH regulation of the endolysosomal TRPML1 channel. *Nat. Struct. Mol. Biol.* **24**, 205-213. doi:10.1038/nsmb.3362
- Li, P., Gu, M. and Xu, H.** (2019). Lysosomal ion channels as decoders of cellular signals. *Trends Biochem. Sci.* **44**, 110-124. doi:10.1016/j.tibs.2018.10.006
- Lie, P. P. Y. and Nixon, R. A.** (2019). Lysosome trafficking and signaling in health and neurodegenerative diseases. *Neurobiol. Dis.* **122**, 94-105. doi:10.1016/j.nbd.2018.05.015
- Lie, P. P. Y., Yang, D. S., Stavrides, P., Goulbourne, C. N., Zheng, P., Mohan, P. S., Cataldo, A. M. and Nixon, R. A.** (2021). Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons. *Cell Rep.* **35**, 109034. doi:10.1016/j.celrep.2021.109034
- Lie, P. P. Y., Yoo, L., Goulbourne, C. N., Berg, M. J., Stavrides, P., Huo, C., Lee, J. H. and Nixon, R. A.** (2022). Axonal transport of late endosomes and amphisomes is selectively modulated by local Ca(2+) efflux and disrupted by PSEN1 loss of function. *Sci. Adv.* **8**, eabj5716. doi:10.1126/sciadv.abj5716
- Lin, Y. T., Seo, J., Gao, F., Feldman, H. M., Wen, H. L., Penney, J., Cam, H. P., Gjonneska, E., Raja, W. K., Cheng, J. et al.** (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. *Neuron* **98**, 1294. doi:10.1016/j.neuron.2018.06.011
- Lines, M. A., Ito, Y., Kernohan, K. D., Mears, W., Hurteau-Miller, J., Venkateswaran, S., Ward, L., Khatchadourian, K., McClintock, J., Bhola, P. et al.** (2017). Yunis-Varon syndrome caused by biallelic VAC14 mutations. *Eur. J. Hum. Genet.* **25**, 1049-1054. doi:10.1038/ejhg.2017.99
- Lloyd-Evans, E. and Platt, F. M.** (2011). Lysosomal Ca(2+) homeostasis: role in pathogenesis of lysosomal storage diseases. *Cell Calcium* **50**, 200-205. doi:10.1016/j.ceca.2011.03.010
- Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Sillence, D. J., Churchill, G. C., Schuchman, E. H., Galione, A. and Platt, F. M.** (2008). Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. *Nat. Med.* **14**, 1247-1255. doi:10.1038/nm.1876
- Malek, M., Kielkowska, A., Chessa, T., Anderson, K. E., Barneda, D., Pir, P., Nakanishi, H., Eguchi, S., Koizumi, A., Sasaki, J. et al.** (2017). PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. *Mol. Cell* **68**, 566-580.e10. doi:10.1016/j.molcel.2017.09.024
- Martin, J. L., Stork, C. J. and Li, Y. V.** (2006). Determining zinc with commonly used calcium and zinc fluorescent indicators, a question on calcium signals. *Cell Calcium* **40**, 393-402. doi:10.1016/j.ceca.2006.04.008
- Martin, S., Harper, C. B., May, L. M., Coulson, E. J., Meunier, F. A. and Osborne, S. L.** (2013). Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death. *PLoS One* **8**, e60152. doi:10.1371/journal.pone.0060152
- Martini-Stoica, H., Cole, A. L., Swartzlander, D. B., Chen, F., Wan, Y. W., Bajaj, L., Bader, D. A., Lee, V. M. Y., Trojanowski, J. Q., Liu, Z. et al.** (2018). TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. *J. Exp. Med.* **215**, 2355-2377. doi:10.1084/jem.20171258

- Mccartney, A. J., Zhang, Y. and Weisman, L. S.** (2014). Phosphatidylinositol 3,5-bisphosphate: low abundance, high significance. *BioEssays* **36**, 52-64. doi:10.1002/bies.201300012
- Medina, D. L., Di Paola, S., Peluso, I., Armani, A., De Stefani, D., Venditti, R., Montefusco, S., Scotto-Rosato, A., Prezioso, C., Forrester, A. et al.** (2015). Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat. Cell Biol.* **17**, 288-299. doi:10.1038/ncb3114
- Michell, R. H., Heath, V. L., Lemmon, M. A. and Dove, S. K.** (2006). Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions. *Trends Biochem. Sci.* **31**, 52-63. doi:10.1016/j.tibs.2005.11.013
- Minckley, T. F., Zhang, C., Fudge, D. H., Dischler, A. M., Lejeune, K. D., Xu, H. and Qin, Y.** (2019). Sub-nanomolar sensitive GzNP3 reveals TRPML1-mediated neuronal Zn(2+) signals. *Nat. Commun.* **10**, 4806. doi:10.1038/s41467-019-12761-x
- Moloney, A. M., Griffin, R. J., Timmons, S., O'connor, R., Ravid, R. and O'Neill, C.** (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. *Neurobiol. Aging* **31**, 224-243. doi:10.1016/j.neurobiolaging.2008.04.002
- Morel, E., Chamoun, Z., Lasiacka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall'armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D. et al.** (2013). Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. *Nat. Commun.* **4**, 2250. doi:10.1038/ncomms3250
- Morgan, A. J., Parrington, J. and Galione, A.** (2012). The luminal Ca(2+) chelator, TPEN, inhibits NAADP-induced Ca(2+) release. *Cell Calcium* **52**, 481-487. doi:10.1016/j.ceca.2012.09.001
- Morioka, S., Nakanishi, H., Yamamoto, T., Hasegawa, J., Tokuda, E., Hikita, T., Sakihara, T., Kugii, Y., Oneyama, C., Yamazaki, M. et al.** (2022). A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation. *Nat. Commun.* **13**, 83. doi:10.1038/s41467-021-27648-z
- Napolitano, G. and Ballabio, A.** (2016). TFEB at a glance. *J. Cell Sci.* **129**, 2475-2481.
- Nicholson, G., Lenk, G. M., Reddel, S. W., Grant, A. E., Towne, C. F., Ferguson, C. J., Simpson, E., Scheuerle, A., Yasick, M., Hoffman, S. et al.** (2011). Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P(2) phosphatase FIG4. *Brain* **134**, 1959-1971. doi:10.1093/brain/awr148
- Nixon, R. A.** (2017). Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. *FASEB J.* **31**, 2729-2743. doi:10.1096/fj.201700359
- Nixon, R. A.** (2020). The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. *Biochim. Biophys. Acta Proteins Proteom.* **1868**, 140443. doi:10.1016/j.bbapap.2020.140443
- Nixon, R. A., Mathews, P. M. and Cotaldo, A. M.** (2001). The neuronal endosomal-lysosomal system in Alzheimer's disease. *J. Alzheimers Dis.* **3**, 97-107. doi:10.3233/JAD-2001-3114
- Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M. et al.** (2017). The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo. *Front. Neurosci.* **11**, 702. doi:10.3389/fnins.2017.00702
- Pensalfini, A., Kim, S., Subbanna, S., Bleiwas, C., Goulbourne, C. N., Stavrides, P. H., Jiang, Y., Lee, J. H., Darji, S., Pawlik, M. et al.** (2020). Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer's disease. *Cell Rep.* **33**, 108420. doi:10.1016/j.celrep.2020.108420
- Pimenova, A. A., Raj, T. and Goate, A. M.** (2018). Untangling genetic risk for Alzheimer's disease. *Biol. Psychiatry* **83**, 300-310. doi:10.1016/j.biopsych.2017.05.014
- Piras, A., Collin, L., Gruninger, F., Graff, C. and Ronnback, A.** (2016). Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. *Acta Neuropathol. Commun.* **4**, 22. doi:10.1186/s40478-016-0292-9
- Polito, V. A., Li, H., Martini-Stoica, H., Wang, B., Yang, L., Xu, Y., Swartzlander, D. B., Palmieri, M., Di Ronza, A., Lee, V. M. et al.** (2014). Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. *EMBO Mol. Med.* **6**, 1142-1160. doi:10.15252/emmm.201303671
- Puertollano, R. and Kiselyov, K.** (2009). TRPMLs: in sickness and in health. *Am. J. Physiol. Renal. Physiol.* **296**, F1245-F1254. doi:10.1152/ajprenal.90522.2008
- Raghu, P., Joseph, A., Krishnan, H., Singh, P. and Saha, S.** (2019). Phosphoinositides: regulators of nervous system function in health and disease. *Front. Mol. Neurosci.* **12**, 208. doi:10.3389/fnmol.2019.00208
- Rautenberg, S., Keller, M., Leser, C., Chen, C. C., Bracher, F. and Grimm, C.** (2022). Expanding the toolbox: novel modulators of endolysosomal cation channels. *Handb. Exp. Pharmacol.* doi:10.1007/164_2022_605
- Saffi, G. T. and Botelho, R. J.** (2019). Lysosome fission: planning for an exit. *Trends Cell Biol.* **29**, 635-646. doi:10.1016/j.tcb.2019.05.003
- Sage, S. O., Pugh, N., Mason, M. J. and Harper, A. G.** (2011). Monitoring the intracellular store Ca²⁺ concentration in agonist-stimulated, intact human platelets by using Fluo-5N. *J. Thromb. Haemost.* **9**, 540-551. doi:10.1111/j.1538-7836.2010.04159.x
- Samie, M. A., Grimm, C., Evans, J. A., Curcio-Morelli, C., Heller, S., Slaugenhaupt, S. A. and Cuajungco, M. P.** (2009). The tissue-specific expression of TRPML2 (MCOLN-2) gene is influenced by the presence of TRPML1. *Pflugers Arch.* **459**, 79-91. doi:10.1007/s00424-009-0716-5
- Schmid, B., Pohn, K. R., Nimsanor, N., Garcia, B. I. A., Poulsen, U., Jorring, I., Rasmussen, M. A., Clausen, C., Mau-Holzmann, U. A., Ramakrishna, S. et al.** (2019). Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line. *Stem Cell Res.* **34**, 101349. doi:10.1016/j.scr.2018.11.010
- See, S. K., Chen, M., Bax, S., Tian, R., Woerman, A., Tse, E., Johnson, I. E., Nowotny, C., Muñoz, E. N., Sengstack, J. et al.** (2021). PIKfyve inhibition blocks endolysosomal escape of α -synuclein fibrils and spread of α -synuclein aggregation. *bioRxiv*. doi:10.1101/2021.01.21.427704
- Shen, D., Wang, X., Li, X., Zhang, X., Yao, Z., Dibble, S., Dong, X. P., Yu, T., Lieberman, A. P., Showalter, H. D. et al.** (2012). Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. *Nat. Commun.* **3**, 731. doi:10.1038/ncomms1735
- Slaugenhaupt, S. A.** (2002). The molecular basis of mucopolipidosis type IV. *Curr. Mol. Med.* **2**, 445-450. doi:10.2174/1566524023362276
- Soares, A. C., Ferreira, A., Marien, J., Delay, C., Lee, E., Trojanowski, J. Q., Moechars, D., Annaert, W. and De Muyneck, L.** (2021). PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding. *J. Biol. Chem.* **296**, 100636. doi:10.1016/j.jbc.2021.100636
- Song, J. X., Malampati, S., Zeng, Y., Durairajan, S. S. K., Yang, C. B., Tong, B. C., Iyaswamy, A., Shang, W. B., Sreenivasamurthy, S. G., Zhu, Z. et al.** (2020). A small molecule transcription factor EB activator ameliorates β -amyloid precursor protein and Tau pathology in Alzheimer's disease models. *Aging Cell* **19**, e13069.
- Stokes, C. E. and Hawthorne, J. N.** (1987). Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. *J. Neurochem.* **48**, 1018-1021. doi:10.1111/j.1471-4159.1987.tb05619.x
- Sun, M., Goldin, E., Stahl, S., Falardeau, J. L., Kennedy, J. C., Acierno, J. S., Jr., Bove, C., Kaneski, C. R., Nagle, J. and Bromley, M. C.** (2000). Mucopolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. *Hum. Mol. Genet.* **9**, 2471-2478. doi:10.1093/hmg/9.17.2471
- Sun, J., Liu, Y., Hao, X., Lin, W., Su, W., Chiang, E., Baudry, M. and Bi, X.** (2022). LAMTOR1 inhibition of TRPML1-dependent lysosomal calcium release regulates dendritic lysosome trafficking and hippocampal neuronal function. *EMBO J.* **41**, e108119.
- Tang, Z., Iojia, E., Bereczki, E., Hulthenby, K., Li, C., Guan, Z., Winblad, B. and Pei, J. J.** (2015). mTOR mediates tau localization and secretion: implication for Alzheimer's disease. *Biochim. Biophys. Acta* **1853**, 1646-1657. doi:10.1016/j.bbamcr.2015.03.003
- Telezkin, V., Schnell, C., Yarova, P., Yung, S., Cope, E., Hughes, A., Thompson, B. A., Sanders, P., Geater, C., Hancock, J. M. et al.** (2016). Forced cell cycle exit and modulation of GABAA, CREB, and GSK3 β signaling promote functional maturation of induced pluripotent stem cell-derived neurons. *Am. J. Physiol. Cell Physiol.* **310**, C520-C541. doi:10.1152/ajpcell.00166.2015
- Thakore, P., Pritchard, H. A. T., Griffin, C. S., Yamasaki, E., Drumm, B. T., Lane, C., Sanders, K. M., Feng Earley, Y. and Earley, S.** (2020). TRPML1 channels initiate Ca(2+) sparks in vascular smooth muscle cells. *Sci. Signal.* **13**, eaba1015. doi:10.1126/scisignal.aba1015
- Thal, D. R., Del Tredici, K., Ludolph, A. C., Hoozemans, J. J., Rozemuller, A. J., Braak, H. and Knippschild, U.** (2011). Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. *Acta Neuropathol.* **122**, 577-589. doi:10.1007/s00401-011-0871-6
- Tsunemi, T., Perez-Rosello, T., Ishiguro, Y., Yoroisaka, A., Jeon, S., Hamada, K., Rammonhan, M., Wong, Y. C., Xie, Z., Akamatsu, W. et al.** (2019). Increased lysosomal exocytosis induced by lysosomal Ca(2+) channel agonists protects human dopaminergic neurons from α -synuclein toxicity. *J. Neurosci.* **39**, 5760-5772. doi:10.1523/JNEUROSCI.3085-18.2019
- Van Acker, Z. P., Bretou, M. and Annaert, W.** (2019). Endo-lysosomal dysregulations and late-onset Alzheimer's disease: impact of genetic risk factors. *Mol. Neurodegener.* **14**, 20. doi:10.1186/s13024-019-0323-7
- Van Weering, J. R. T. and Scheper, W.** (2019). Endolysosome and autolysosome dysfunction in Alzheimer's Disease: where intracellular and extracellular meet. *CNS Drugs* **33**, 639-648. doi:10.1007/s40263-019-00643-1
- Vanhaesebroeck, B., Stephens, L. and Hawkins, P.** (2012). PI3K signalling: the path to discovery and understanding. *Nat. Rev. Mol. Cell Biol.* **13**, 195-203. doi:10.1038/nrm3290
- Venkatachalam, K., Wong, C. O. and Zhu, M. X.** (2015). The role of TRPMLs in endolysosomal trafficking and function. *Cell Calcium* **58**, 48-56. doi:10.1016/j.ceca.2014.10.008
- Waller-Evans, H. and Lloyd-Evans, E.** (2015). Regulation of TRPML1 function. *Biochem. Soc. Trans.* **43**, 442-446. doi:10.1042/BST20140311
- Wartosch, L., Bright, N. A. and Luzio, J. P.** (2015). Lysosomes. *Curr. Biol.* **25**, R315-R316. doi:10.1016/j.cub.2015.02.027

- Whyte, L. S., Lau, A. A., Hemsley, K. M., Hopwood, J. J. and Sargeant, T. J. (2017). Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease? *J. Neurochem.* **140**, 703-717. doi:10.1111/jnc.13935
- Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., Plattner, F. and Herz, J. (2018). Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease. *Elife* **7**, e40048. doi:10.7554/eLife.40048
- Xiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Tripoli, D. L., Czerniewski, L., Ballabio, A. et al. (2015). Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing a β generation and amyloid plaque pathogenesis. *J. Neurosci.* **35**, 12137-12151. doi:10.1523/JNEUROSCI.0705-15.2015
- Xu, Y., Du, S., Marsh, J. A., Horie, K., Sato, C., Ballabio, A., Karch, C. M., Holtzman, D. M. and Zheng, H. (2020). TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. *Mol. Psychiatry* **26**, 5925-5939. doi:10.1038/s41380-020-0738-0
- Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. and Tashiro, Y. (1991). Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. *J. Biol. Chem.* **266**, 17707-17712. doi:10.1016/S0021-9258(19)47429-2
- Zhang, X., Chow, C. Y., Sahenk, Z., Shy, M. E., Meisler, M. H. and Li, J. (2008). Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. *Brain* **131**, 1990-2001. doi:10.1093/brain/awn114
- Zhang, X., Li, X. and Xu, H. (2012). Phosphoinositide isoforms determine compartment-specific ion channel activity. *Proc. Natl. Acad. Sci. USA* **109**, 11384-11389. doi:10.1073/pnas.1202194109
- Zhang, X., Cheng, X., Yu, L., Yang, J., Calvo, R., Patnaik, S., Hu, X., Gao, Q., Yang, M., Lawas, M. et al. (2016). MCOLN1 is a ROS sensor in lysosomes that regulates autophagy. *Nat. Commun.* **7**, 12109. doi:10.1038/ncomms12109
- Zhu, L., Zhong, M., Elder, G. A., Sano, M., Holtzman, D. M., Gandy, S., Cardozo, C., Haroutunian, V., Robakis, N. K. and Cai, D. (2015). Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. *Proc. Natl. Acad. Sci. USA* **112**, 11965-11970. doi:10.1073/pnas.1510011112
- Zou, J., Hu, B., Arpag, S., Yan, Q., Hamilton, A., Zeng, Y. S., Vanoye, C. G. and Li, J. (2015). Reactivation of lysosomal Ca²⁺ efflux rescues abnormal lysosomal storage in FIG4-deficient cells. *J. Neurosci.* **35**, 6801-6812. doi:10.1523/JNEUROSCI.4442-14.2015